Preface

Oral diseases are a prevalent health issue, both communicable and non-communicable, that can cause pain, discomfort, disfigurement, and even death, posing a significant health burden for many countries. According to the WHO, almost 3.5 billion people worldwide are affected by oral diseases. This number may be even higher in developing countries, where a lack of awareness among the public, inadequate infrastructure, and limited access to oral healthcare providers, especially for individuals of lower socio-economic status, may contribute to increased prevalence. Periodontology is a specialized field of dentistry that deals with the health and disease of the periodontium, which includes the teeth and their supporting structures. The maintenance of a healthy periodontium is crucial for preserving dentition integrity. Over the years, there have been several essential advances in the pathophysiology, classification, diagnosis, and management of periodontal disease.

This book aims to provide researchers and clinicians with an overview of the most recent insights regarding the periodontium and periodontal diseases. The book contains various chapters that cover newer diagnosis and treatment modalities, as well as contributing to the understanding of the molecular aspects of periodontal disease.

> **Gokul Sridharan, MDS, Ph.D., PGD (Medical Law and Ethics)** Department of Oral Pathology and Microbiology, Dr. G. D. Pol Foundation YMT Dental College and Hospital, Navi Mumbai, India

## **Chapter 1** The Salivary Secretome

*Luís Perpétuo, Rita Ferreira, Sofia Guedes, Francisco Amado and Rui Vitorino*

## **Abstract**

Recently, proteomics has emerged as an important tool for understanding biological systems, protein–protein interactions, and networks that ultimately lead to a deeper understanding of the underlying mechanisms of certain diseases. More recently, the study of secretomes, a type of proteomics, has also been highlighted as a potential next step in the field of diagnosis/prognosis. The secretome is the set of proteins expressed by an organism and secreted into the extracellular space, comprising 13–20% of all proteins. Since almost all, if not all, organs produce secretomes, this means that it is possible to study secretomes and trace these proteins back to their origin, supporting the idea that this could indeed be very important in diagnosing certain diseases. This is often combined with techniques such as mass spectrometry to measure the secretome of, for example, a particular tissue, and bioinformatics tools and databases to give us an idea of what to expect (prediction). In this paper, we will give a general overview of this world, but with a focus on the new bioinformatics tools and databases, their advantages and disadvantages, as well as a deeper look at isolation systems for proteomes, specifically salivary secretomes. Indeed, the salivary secretome represents a valuable new tool capable of providing insights into immunopathology and potentially aiding in diagnostics. Furthermore, we will explore applications of these methods and give an idea of what the future holds for such promising techniques: Salivary secretome in conjunction with bioinformatics tools/databases in the diagnosis of diseases (such as diabetes, Sjogren's syndrome, and cardiovascular disease).

**Keywords:** Saliva, bioinformatic tools, prediction

## **1. Introduction**

Salivary plasma is also known as ultrafiltrate of biological fluid. Nearly 1,000 different proteins and 19,000 unique peptide sequences have been found in saliva. Whole saliva (WMS) is a combination of various secretions produced by major and minor salivary glands, gingiva cervical fluid (GCF), mucosal transmission, oral wound serum and blood vessels [1].

Saliva is mainly composed of three main pairs of salivary glands, namely the parotid gland, the sublingual gland, and the lingual gland. Saliva is composed of 99.5% water, 0.3% protein and 0.2% trace elements. The concentration of proteins and peptides in saliva is very important for the maintenance of oral health and homeostasis. The increased frequency and severity of oral diseases are often related to changes in salivary protein content [2, 3]. Salivary proteins facilitate food perception and digestion, maintain the integrity of mineralized tooth and oral epithelial surfaces, shield the oral digestive tract from environmental hazards and invading pathogens, and protect oral tissues from fungal or viral infections [4, 5]. Moreover, it is suggested that the origins of salivary proteins can be analyzed throughout mixed saliva and that post-transcriptional modifications may play a key role in understanding secretome network pathways [6, 7]. Moreover, Feizi et al., 2020 [7] found that the study of secretion pathways (translocation, folding, trafficking and glycosylation) is relevant to know tissue-specific secretion pathways and tissue-specific secretomes that would facilitate the elaboration of a link between proteins and diseases.

Salivary gland secretome represents a valuable new tool to measure many local soluble mediators to gain future insight into immunopathology and potentially aid in diagnosis [8]. This method could be of use to identify therapeutic targets and develop markers for stratification, prognosis and treatment response in patients [9, 10].

Biomarkers are defined as biological molecules found in blood, saliva, and other body fluids, as symptoms of normal or abnormal processes, or symptoms of conditions or diseases. Few studies have demonstrated the relationship between serum and saliva levels of clinically used biomarkers. Nevertheless, human saliva has attracted attention as a liquid biopsy for the diagnosis of oral diseases as a potential target. Salivary biomarkers are used for evaluation, prediction and diagnosis of various diseases. They can be collected rapidly in a non-invasive, natural and painless way. Salivary research can help identify biomarkers associated with health and disease conditions [1, 11, 12]. Collection and storage of saliva is also simple, relatively cheap and low risk for patients and healthcare professionals [3, 13, 14]. Salivary proteomics is a promising tool as proteomic molecules control the direct antibacterial action of microorganisms in the oral cavity, but has limitations including non-applicability in the driest patients and technical challenges such as the degradation of cytokines by salivary enzymes [9]. Optimization of existing histology protocols to determine salivary gland inflammation will help improve the diagnosis of various diseases [9, 10].

## **2. Definition**

Under both normal and pathological conditions, cells secrete a variety of proteins into the extracellular space via classical and non-classical secretory pathways [5]. The majority of these proteins represent the pathophysiology of the cell from which they are secreted. Recently, although more than 92% of protein-coding genes have been mapped by the Human Proteome Map Project, a large number of these proteins that constitute the cell's secretome is still unknown [4].

Secreted proteins or the secretome may be accessible in body fluids and are therefore considered as potential biomarkers to distinguish between healthy and diseased individuals [8]. To facilitate biomarker discovery and further assist clinicians and scientists working in these areas, we compiled and cataloged secreted proteins from the human proteome using an integrated bioinformatics approach [9, 10]. In this study, it was found that nearly 14% of the human proteome is likely secreted via classical and non-classical secretion pathways. Of these, ~38% of these secreted proteins were found in extracellular vesicles including exosomes and shedding microvesicles.

Of these secreted proteins, 94% were detected in human body fluids including blood, plasma, serum, saliva, semen, tears, and urine. We hypothesize that this list of secreted proteins with high confidence could serve as a compendium of biomarker

### *The Salivary Secretome DOI: http://dx.doi.org/10.5772/intechopen.98278*

candidates. In addition, the catalog could provide functional insights into understanding the molecular mechanisms involved in various physiological and pathophysiological conditions.

The highly elevated inflammatory mediators in the secretions of patients with complex diseases such as primary Sjögren's syndrome (PSS) are related to clinical parameters.

### **2.1 Secreted proteins**

A secreted protein can be defined as a protein that is actively transported outside the cell. In humans, cells such as endocrine cells and B lymphocytes are specialized in the secretion of proteins, most cells secrete proteins in different. Not only is this a rich source of new treatments and drug targets, but most of the blood diagnostic tests used in the clinic target secreted proteins, underscoring the importance of these proteins to medicine and biology. These include pancreatic enzymes (PRSS1, CELA3A, AMY2A) and other digestive enzymes expressed in the salivary glands (PRR4, STATH, ZG16B) or stomach (PGA3, PGA4). The liver is one of the most important secretory organs and produces high amounts of plasma proteins such as albumin, fibrinogen and transferrin. Another group of highly secreted proteins belongs to the diphenhydramine family and is secreted by glandular cells in the epididymis (DEFB118, DEFB106A and DEFB129).

### **2.2 Membrane proteins**

Membrane proteins are one of the largest and most important classes of proteins. Membrane proteins are associated with cell membranes or organs in cells and can be classified as peripheral or integrated. Peripheral membrane proteins bind to the membrane by binding to the peripheral region of the membrane or by integrated membrane proteins, but cannot completely penetrate the membrane. Integrated membrane proteins have a hydrophobic α-helical or β-barrel structure so that they can be distributed throughout the lipid molecule and linked by the outer loop region of the membrane. The α-helical integral membrane protein is the main type of membrane protein and is found in all types of biological membranes. This explains why their key roles as transporters and receptors currently account for about 57% of approved drug targets, as they are of great importance to the pharmaceutical industry. Many important receptors and cell surface molecules are found in the list of human cell differentiation molecules (CD markers). The G protein synthesis receptor (GPCR) comprises seven transmembrane fragments (DM) and contains 775 human protein-coding genes, making it the largest membrane protein target.

### **2.3 Classification of the human proteome**

Despite the availability of the human salivary proteome, the origin of individual proteins remains unclear. So far, more than 3000 proteins have been identified in various studies, and with new tools and methods, more will be identified [4].

Meinken et al., 2015 [15] analyzed the subcellular location of the protein using MetazSecKB. The subcellular location of the protein is an important factor that determines the function of the protein molecule in the organism. MetazSecKB is a knowledge base for subcellular proteins developed specifically for metazoans (i.e., humans and animals). More than 4 million protein sequence data entries have been retrieved from UniProt, including 121 complete proteins. The location of protein

subgroups, including secretion and 15 subgroup sites, are assigned based on selected test evidence or predictions using 7 computational tools [15].

Various identifiers, gene names, keywords and types can be used to search and download protein or subcellular protein data. Support BLAST search and community annotation of sublocalizations. Our preliminary analysis shows that protein levels, secretome levels, and other subcellular protein levels vary widely among different animal species. Confidentiality levels range from 3–22% (mean 8%) in Metazzoa species [15].

Approximately 21–43% (mean 31%) in cytoplasm, 20–37% (mean 30%) in embryo, 3–19% (mean 12%) plasma membrane proteins and 3–9% (mean 6%) in mitochondria. The authors also compared protein families in different animal species [15]. Genetic oncology of human secreted proteins and field analysis of protein families show that these proteins play an important role in the development of human structure, signal transduction and regulation of many biological processes in the immune system [15].

The combination of the results of membrane protein and secretion analysis draws the distribution map of potential membrane proteins and secreted proteins in human membrane proteins. Three types are used to annotate the protein isoforms of all human genes: (i) secreted type, (ii) membrane type, and (iii) endogenous type (i.e., proteins with no predictable SP/TM properties). Note that proteins classified as membranous may be localized in the endoplasmic reticulum or in the inner membrane, such as the colon. Each human protein-coding gene is classified as having all isoforms encoding protein isoforms belonging to one or two or three types of these groups. The results showed that at least 36% of the predicted human genes contain membranedisseminated or secreted protein isoforms.

### **2.4 The plasma proteome**

Plasma is the transparent, liquid part of blood that is formed when white blood cells, red blood cells, and platelets are removed. It consists of small substances such as water (90%), protein (7–8%), salt, gas, and nutrients. Plasma proteins contain up to 90% of the ten most abundant proteins, including albumin, fibrinogen, which is involved in blood clotting, and immunoglobulin, which is mainly involved in immune processes. One of the most important functions of plasma is to transport essential compounds to different parts of the body, regulate osmotic pressure and fluid exchange in all tissues, and play an important role in immune system function. Most cells in the body interact with plasma directly or indirectly through other fluids. Therefore, analysis of plasma proteins can provide important information about the patient's health status.

The dynamic range of plasma protein between the high albumin (ALB) concentration is more than 10 orders of magnitude. It has an extraordinary dynamic range. It can serve as a transporter and helps maintain the osmotic pressure of emulsification. Rare proteins containing interleukins are found in tissues. Although many proteins in the plasma proteome pass through the secretory pathway, there is another type of tissue-secreted proteins that are found in cells but can be released into plasma due to cell death or damage. There is also an interesting class of proteins that do not enter the ER/Golgi pathway by non-classical secretion and include cytokines such as interleukin 10 (IL10) and mitogens such as fibroblast growth factor 2 (FGF2).

### **2.5 The secretory pathway**

In the secretory pathway, the signal sequence protein travels from the endoplasmic reticulum (ER) through the vesicles of the ER to the cell surface. The signal

### *The Salivary Secretome DOI: http://dx.doi.org/10.5772/intechopen.98278*

sequence that drives protein secretion is called a signal peptide. It is a short hydrophobic N-terminus that is inserted into the ER membrane and separated from the protein. In most cases, the N-terminal transmembrane (TM) acts as part of the signal line. The ER signal sequence is recognized by the chaperone protein, which guides the ribosome to the approximate ER where transfer of the protein sequence takes place in a protein complex called the translocon. The membrane protein is transferred by the translocation protein to the lipid player of the ER membrane, and the secreted protein is transferred into the lumen of ER. Proteins that pass the quality control of ER are transported by vesicles to the Golgi, where they are further modified in important processes such as glycosylation and phosphorylation. The Golgi is also responsible for sorting proteins for transport to their final destination. These proteins are usually plasma membranes, lysosomes or cell secretions.

## **3. Systems for isolation**

With the use of novel advanced technologies, many oral and systemic diseases can be treated early with non-invasive, easy to follow, time-saving and personalized solutions, further enhancing the potential of salivary secretome [16].

## **3.1 Common methods used to identify salivary secretome**

Salivary secretome mainly includes proteins, metabolites, genes, microorganisms and immune system. Various methods are used to analyze molecules to study and verify biomarkers. Proteins can be used to diagnose diabetes, periodontitis, dental caries and AIDS [16, 17]. However, salivary transcriptome and genes include mRNA and DNA. Genetic chip sequencing, DNA hybridization, qPCR and gel electrophoresis help in identifying various diseases. On the other hand, metabolic research requires and uses gas chromatography–mass spectrometry, nuclear magnetic resonance spectroscopy and high-performance liquid chromatography. These methods can be used to diagnose diabetes, lung cancer, pancreatic cancer, breast cancer and Sjogren's syndrome [17, 18].

## **3.2 Saliva biomarker-based platforms**

The analysis system is based on different technologies used to detect biomarkers in saliva. Single and multiple systems (e.g. MEMS, ORI, chromatographic test strips and multiple salivary glands (US)) are only used to detect proteins and whole proteins and nucleic acids (e.g. IL -8, MMP-8, α-amylase, e.g. IV, HCV) up to 1 minute [19], and there is a short time limit. Therefore, these technologies have reduced the aggressive behavior to a higher level [19].

## **3.3 Novel isolation techniques**

Biosensor is a biological analyzer that can replicate any biological material. The biosensor works by biometrically identifying specific components and is designed for target analysis. They remain selective and sensitive to the presence of other interfering compounds. In the medical field, the application of biosensors is growing rapidly [20, 21]. They can detect antibodies/antigens, nucleic acids, cell structures or enzymes. The transducers can be electrochemical, thermometric, optical, piezoelectric or magnetic.

## **3.4 Automated mass spectrometry-based approach**

Using liquid chromatography–tandem mass spectrometry (LC -MS/MS) to identify novel targets in specially prepared cell secretions, Wetie et al., 2013 [22] have developed an automated, simple and effective strategy. In addition, the supporting role of mass spectrometry (MS) in the functional evaluation of the identified secreted targets is investigated [22].

Simplicity is achieved by culturing cells in serum-free medium, which eliminates the need to remove large amounts of serum protein while minimizing unsightly matrix effects. Once these factors have been determined, their verification and nature is followed. In addition, this method can lead to the identification of abnormally secreted, spilled or exaggerated proteins in response to stimuli [22].

### **3.5 BioMEMS**

The lab-on-a-chip system uses small and easy-to-build BioMEMS devices to detect biological and chemical agents. They are based on micro/nano scale fabrication systems and help to improve the sensitivity of sensor results. It has unlabeled detection technology including microconverter, surface plasmon oscillation and organic field effect transistors [23, 24].

Biological Micro-Electro-Mechanical Systems (MEMS) can be used in many applications, such as drug delivery, heart MEMS, hearing aids, insulin microbumps, endoscopic lens agents, and retinal prostheses for monitoring patients with heart disease [25].

### **3.6 Fluorescent biosensors**

Fluorescent biosensors can be used in cancer, drug development, arthritis, cardiovascular and viral infections, chronic myeloid leukemia, etc. Efficient screening methods, applications of fluorescence studies in gene expression, protein location in cell cycle, cell apoptosis, signal transduction and transcription [26]. Nanomaterials and nanoproducts for biosensors offer opportunities for the next generation of biosensing. They can be widely used for monitoring, diagnosis, control and analysis [27].

### **3.7 Electrical field-induced release and measurement (EFIRM)**

The liquid biopsy technique called EFIRM uses electrochemical methods to promote hybridization of nucleic acids [28]. This method enables precise detection of RNA and protein biomarker targets on exosomes. EFIRM can analyze mutation status within one hour without extracting DNA. It can detect cancer in oral cavity cancer, non-squamous lung cancer and epidermal growth factor (EGFR) mutations [29].

### **3.8 Microfluidics**

Microfluidic applications work with integrated micromachining and specific physical and chemical properties. Originally, silicone, mineral glass and ceramics were used. These materials were replaced by soft and hard thermostatic and thermoplastic materials or biodegradable hydrogel materials.

The paper analytical device (μPADs) was first developed by Whiteside. Paper is microscopic and hydrophilic, so it provides the basis for the formation of microscopic channels. They are used to diagnose urine metabolism, blood glucose, pH, liver function and infectious agents [30].

## **4. Interaction with other systems**

Saliva is a potential diagnostic tool that can provide a simple diagnostic method. The presence of salivary biomarkers can aid in early diagnosis. Saliva has the potential to revolutionize next-generation molecular testing. It can diagnose oral cancer, dental inflammation and periodontitis [31]. To date, many salivary biomarkers have been proposed for the diagnosis of oral cancer. Conventional medical standards are not sufficient to easily determine the location of active disease or to easily measure the progress of future disease. Genetic testing offers the most effective way to prevent dental disease in the long term [31–33].

In addition, several research groups have reported the use of whole saliva or glandular saliva for mass spectrometry-based proteomics research. The extensive enumeration of salivary proteins is done by combining the previous LC -MS/MS -based saliva research data with our research data [34].

Using the bioinformatics tools mentioned above, a possible analysis of gene ontology classification and their secretion was performed. Comparing with the latest human salivary proteins synthesized from oral cancer tissues expressing different proteins, we found proteins associated with oral cancer. The protein peptides of these proteinsor the most observed peptides were selected from the Global Protein Machine Database (GPMDP) [35].

## **5. Bioinformatics tools for secretome prediction**

Proteins can flow from blood to salivary glands by active transport, passive diffusion, or ultrafiltration, and then some of them are released into saliva, so if accurately identified, they can be used as biomarkers of disease [36]. Researchers have developed a series of novel computational and biological communication tools to predict salivary biomarkers [37].

The basis of the prediction is a set of physicochemical and hierarchical features found between human proteins that can pass from blood to saliva and proteins that are not present in saliva [36, 37]. In 2013, Wang et al., [38] predicted human salivary proteins from blood and evaluated their use in identifying diagnostic biomarkers. This predictive capability can be used to predict potential biomarker proteins for specific human diseases, information about various exposed proteins in diseased and healthy control tissues, and the prognostic potential of proteins secreted in blood. This enables the use of antibody-based technology to target effective biomarkers in saliva. They used this comprehensive data to predict that 31 candidate biomarker proteins in saliva could be used in breast cancer [38].

### **5.1 Bioinformatic tools**

Continued method development supports the comprehensive identification and quantification of secreted proteins at specific cellular levels. The role of secretory factors in regulating important signaling events has been discussed, and a connectivity diagram has been constructed to describe differential secretory expression and dynamic changes [39].

Bioinformatics has become a bridge between confidential data and computer tasks to manage, mine and retrieve information. Based on this information, predictions can be made to help clarify the physiological state of a particular organism and determine

the specific dysfunction at the stage of disease. The major challenge in data analysis lies within the integration of biological information from different sources. Database enhancements and software improvements can greatly increase the practicality and reliability of confidential investigations [39]. Reliable data interpretation is essential for the formation and exploration of relevant disease biomarker proposals as well as the discovery of new drug targets. Using genetic oncology (GO), it is possible to collect basic information about secretome proteins. GO analysis can determine how the identified components relate to specific functions or processes and whether a particular type of protein is found in secretions. In addition, in a statistical framework, the method GO can determine whether there is an obvious GO period [40]. In the database GO, molecular functions are defined as the biochemical functions of gene products. The biological pathway refers to the integration of the biochemical properties of proteins. Pathway analysis is an important step to properly understand the uniqueness and function of secrets. Methods have been developed to assess whether protein packaging is present in the target phenotype. Using different tools, according to different group rules, can provide different and sometimes complementary information. The results are strongly influenced by the criteria chosen to define the target protein and the reference list [40, 41].

Ingenuity Path Analysis (IPA) and Meta Core (Genico) are commercial software for visualizing high performance data in a biological network environment. STRING is a free database of known and predicted protein interactions, including direct (physical) and indirect (functional) associations from various sources [42]. In this way, the network of protein–protein interaction, metabolism or genetic regulation can be reconstructed based on prior knowledge and the biological network can be reconstructed. Determined by the interaction between its components [42, 43].

Pathway analysis tools become very popular and can interpret omics data quickly. To date, IPA has been highly cited in the field of proteomics, having been used in 121 publications. The software is designed to interpret large genetic datasets, but it can also be used to illustrate the biological implications of complex proteomics datasets [43].

Data sharing presents a new challenge for modern proteomics. The first obstacle to data sharing is the data format. Each MS tool generates a file from the source data in a proprietary format. The HUPO-PSI standard has been accepted by vendors and public web-based resource providers. The proteomics community has developed guidelines to facilitate storage and open access to proteomics data in a central public repository [44–46].

PeptideAtlas, PRIDE and Trench have been developed to share data among the entire proteomics research community [47–49]. Recently, the Proteome Change Alliance has established a place where MS proteomics data can be submitted to the existing major proteomics databases. The purpose is to facilitate data transfer between them to achieve the best data transfer and to create a global accession number for all participating databases. This information will be available to all MS/MS researchers in the UK who wish to use it for their research [47–49].

Using the innovative majority voting methods, Rehman et al., 2020, analyzed transcriptome data from 5 cancer types and more than 3000 samples to measure the relative difference in gene expression of secretory proteins compared to normal tissue in the vicinity. A comprehensive, in-depth data mining analysis reveals that among several cancer types, a continuous group of uncontrolled secretory protein subtypes is concentrated in hematopoietic cell lines. Genes associated with hematopoietic cell lineages are often reduced during the continuous development of cancer, and high exposure levels are associated with good prognosis for patients [50].

### *The Salivary Secretome DOI: http://dx.doi.org/10.5772/intechopen.98278*

Moreover, they suggest that cancer cells suppress the underlying mechanism of hematopoietic cell lineage signaling by reducing the expression of immune-related genes. The data identify potential biomarkers for cancer immunotherapy. It can be concluded that this method is applicable to define other cancers and highlight specific targets for treatment and diagnosis [50].

### **5.2 BONCAT and pulsed SILAC**

Despite the increasing interest in secretomes associated with paracrine/autocrine mechanisms, mass spectrometric cell studies have been performed using serum-free media (SFM). On the other hand, the use of serum culture medium (SCM) is not necessarily recommended because secretions obtained with SCM are easily contaminated with fetal serum proteins (FBS) [51].

Shin et al., 2019, [51] used biological non-designated amino acid tags (BONCAT) and pulsed SILAC (pSILAC) to analyze the different secreted proteins between SFM and SCM. Mesenchymal stem cells are derived from human cancer cells U87MG and human Wharton's Jelly (hWJ-MSCs) [51]. In most cases, the biological communication equipment predicts that the protein is secreted when the protein secretion level in SCM is higher than in SFM. In HWJ-MSC, the amount of protein secreted in SCM within 24 hours, even considering different cell proliferation rates, is greater than SFM [51]. The highly secreted HWJ-MSC protein in SCM contains many positive markers of angiogenesis, neurogenesis and osteogenesis, as well as MSc-paracrine factors involved in upstream regulators of cell proliferation. This result indicates that secretome analysis should be processed in SCM to promote cell proliferation and secretion [51].

Another computational method was evaluated by Min, 2010 [52] to understand the prediction accuracy of signal B, phobia, target B and wolf sport, which can be used alone or in combination with DMHMM and PS scanning. Prediction accuracy is represented by Mathews Correlation Coefficient (MCC). Tools for predicting proteins secreted in different eukaryotic kingdoms show different advantages. Using his own tools, the author found Wolfsport for fungi (73.1%), Phobius for animals (82.8%), Signal B for plants (55.4%) and Phobius for proteases (42.1%) [52].

The use of TMHMM significantly improves the prediction accuracy of all datasets. According to the measured accuracy, it is recommended to use the following methods to make secret predictions for different eukaryotes: signal P/DMHM/wolfport/ Phobius/PS scan for fungi (83.4%), Phobius/wolfb/animal/PS -86A Phobius/target P/ PS scan (73.2%), combined with all tools for protists (52.8%) [52].

Free interactive resources are provided within the portal Human Protein Atlas (www. proteinatlas.org) and analyzed by Uhlén et al., 2015 [53]. The portal offers the possibility to explore tissue-expressed proteins in tissues and organs and to analyze tissue profiles for specific protein classes. A large list of proteins expressed at high levels in different tissues was compiled to localize the protein in the subunits of each tissue and organ and provide a spatial environment down to the level of individual cells [53].

## **6. Applications**

Saliva is a complex fluid containing various enzymes, electrolytes, proteins, nucleic acids, antibacterial components, hormones, cytokines, and antibodies.

Its composition almost reflects the overall state of physical health and disease. It can become a diagnostic tool for many diseases. The submandibular saliva of patients with cystic fibrosis contains 66% more lipids per 100 milliliters of saliva than healthy substances. Salivary fatty acid profile can be used as a good indicator for early detection of heart disease.

Under normal and pathological conditions, cells secrete various types of proteins into the extracellular space via classical and nonclassical secretory pathways. Most of these proteins represent cell secretion pathologies. Recently, Human Protein Atlas Project has localized more than 92% of protein-coding genes, but the number of proteins secreted by cells is still difficult to determine [54]. Secreted proteins or secretions can enter body fluids and are therefore considered as potential biomarkers to distinguish healthy and diseased individuals. To facilitate the discovery of biomarkers and to further assist physicians and scientists working in this field, Keerthikumar et al., 2016, [54] used integrated bioinformatics methods to compile and list the secreted proteins in humans.

In this study, it was found that about 14% of human proteins can be secreted through classical and non-classical secretion pathways. Among them, about 38% of secreted proteins are in extracellular cells, including exosomes and excretory microorganisms. Of these secreted proteins, 94% are present in human body fluids, including blood, plasma, serum, saliva, semen, tears, and urine [54]. The author hypothesizes that this list of secreted proteins can serve as a set of candidate biomarkers with high confidence. They can provide functional insights to understand the molecular mechanisms associated with various physiological and pathophysiological states of cells [54].

Chen et al., 2019, [55] found that secretory proteins are widely expressed in various tissues and body fluids, and a large proportion of them are expressed in a tissue-specific manner. In addition, there are 14 cancer-related secretory proteins. Their expression levels are significantly correlated with survival rates of patients with eight different tumors, which may be potential prognostic biomarkers [55]. Surprisingly, of the 6,943 secretory proteins, 89.21% (2,927 novel secretory proteins) have known protein domains [55]. The authors enriched these novel secretory proteins mainly by known domains related to immunity (such as immunoglobulin V set and C1 set domains). Their comprehensive novel secretory proteins and features provide insight into human confidentiality and are valuable resources for future research [55].

In Sjogren's syndrome, salivary flow is impaired due to tubular changes caused by lymphocyte infiltration and salivary gland fibrosis, and the patient suffers from toothache, infectious dysphagia, and other oral complaints. The blood lipid level of Sjogren's patients is twice that of normal healthy people, and the antibody level is high. Patients with Sjogren's syndrome or radiation therapy for head and neck cancer have severe dry mouth, which greatly affects their oral health and quality of life. Since there is no clinically proven treatment, clinical management of xerostomia is limited to preventive treatment. Previous research has shown that mesenchymal stem cells (MMSC) derived from mouse bone marrow differ from salivary progenitors when grown together with mouse salivary epithelial cells [56]. Restrictive transcription factors in co-grown MMSCs are identified with amylase (AMY1), muscarinic 3 receptors (M3R), aquaporin 5 (AQP5), tubular morphological changes, and acinar cell marker expression [56]. This cell marker is called cytokeratin 19 (CK19). Mona et al., 2020, investigated inducible molecules in a conditioned medium that can trigger MMSC replication and integrated mass spectrometry and systems biology by high

**Table 1.** *Bioinformatics tools and databases that predict secreted proteins.* performance liquid chromatography. Based on their key roles in embryonic development and salivary gland growth, our method identified ten differentially expressed proteins [56]. In addition, systems biology analysis revealed six candidate proteins, namely cysteine-rich insulin-like growth factor binding protein 7 (IgFPP7), proangiogenic stimulant 61 (CYR61), acrin (AGRN), laminin, beta 2 (LAMP2), folistatin 1 (FSDL1) and fibronectin 1 (FN1), all of which could potentially contribute to the propagation of MMSC during co-cultivation [56].

Human salivary secretome plays a diagnostic role in the diagnosis of heart disease. Diabetes is another common disease that is rapidly developing worldwide. Due to its non-invasiveness, cheap and simple saliva samples are attractive as diagnostic fluids for diabetes analysis. The announced study concluded that various biomarkers are used in the early stages to diagnose diabetes. Compared to serum of diabetic and diabetic patients, salivary glucose, amylase, calcium, phosphorus and calcium levels show significant changes.

Salivary secretome test requires proper identification and verification of biomarkers. Diagnosis and biomarkers are measurable parameters that can interact physiologically and biochemically at the molecular or cellular level and always serve as normal indicators. The pathology and intervention behavior of the human body can be identified using biomarkers present in salivary secretome. Biomarkers include many categories, such as protein, DNA, RNA, metabolism and microorganisms, so they are all used together (**Table 1**).

## **7. Future perspectives**

With our current results, we note that although the secretome has gained attention and has been highlighted in recent studies, it is still of interest to explore this topic more deeply. In future studies, we propose to go beyond the usual protein profiling and perform network studies to find links between proteins from salivary secretome in direct and indirect ways. In addition, studies have begun to evaluate the role that transcriptional and post-transcriptional modifications of proteins have in informing their origin [6, 7]. This will be relevant for establishing links between salivary protein levels and disease prognosis/diagnosis.

In **Figure 1**, we see a flowchart of the information presented in this paper. Starting from a secretome: how do we detect it (detection approach), how do we identify it (protein identification), how do we verify information about these proteins (record repositories and inventory of the secretome). This line of work leads to the analysis of the secretome, but makes up only part of the pipeline. Prediction tools are also of great use (genomic datasets enable the existence of tools to predict secretory proteins). Several of the bioinformatics tools discussed previously can be used to perform secretome analysis, where we can limit the investigation to protein profiling, but also go beyond that to investigate signaling pathways, networks (protein–protein, gene-protein, protein-disease), and determine useful disease biomarkers. All of this information culminates in getting closer to the biological significance of certain proteins and interactions under certain circumstances. **Figure 1** shows several examples of biomarkers mentioned in this review and narrows that down to applications for saliva testing, namely in areas such as prognosis and diagnosis. In summary, **Figure 1** represents the pipeline and workflow of secretome studies.

### *The Salivary Secretome DOI: http://dx.doi.org/10.5772/intechopen.98278*

### **Figure 1.**

*Workflow of secretome analysis for the comprehensive characterization of molecules secreted by salivary glands, arriving at the final point (biomarkers) that can be used for prognosis/diagnosis in several diseases.*

## **8. Conclusion**

Although there are some limitations, salivary proteomics is a promising diagnostic and therapeutic tool for several critical diseases. Salivary gland secretome represents a valuable new tool to measure many local soluble mediators, provide future insight into immunopathology, and potentially aid in diagnosis.

Routine laboratory tests include hematology, clinical chemistry, and immunochemistry using high performance equipment. Diagnosis based on salivary secretome may provide an efficient, rapid and simple automated method for transformation. The next decade will bring improvements in accuracy, performance, and bed monitoring, but not hospital systems.

Improving basic healthcare systems with personalized medications, biosensors, labon-a-chip systems, personal genetics, and smartphone tracking parameters. The impact of saliva testing on healthcare systems is enormous, aggressive and convenient.

### **Figure 2.**

*Take-home messages that summarize the main ideas/concepts of this paper.*

Reportedly, the ability to use saliva for a liquid biopsy is an important diagnostic tool for medical conditions and dental diseases. The simple model has information related to non-aggression and physical health, making it an attractive choice.

Some of the salivary secretome markers mentioned in this review are general markers, not specific to particular diseases. A more specific set of markers is needed to make salivary secretome an acceptable diagnostic fluid. The recent introduction of the programmable bio-nanochip system (P-PNC) has driven the revolution in saliva detection technology for the detection of cardiovascular disease (CVD).

Other biosensing systems, such as cardiac microelectromechanical systems (MEMS), can also be used to detect certain diseases. With the help of the latest labs in chip systems, they will improve hospital practice and human health [57]. Future development of this diagnostic tool will lead to further improvements in certain devices that will change the method of screening for critical diseases such as CVD.

A take-home message that summarizes, as shown in **Figure 2**, the main issues that have been addressed so far in salivary proteomics as a diagnostic and therapeutic tool. It also includes the means of detection and prediction of salivary proteomics (biosensors and bioinformatics tools). Although some have been used for a long time, most are novel tools and techniques that have been shown to provide great data to support proteomics studies. In addition, **Figure 2** provides a short list of the most promising and relevant salivary biomarkers discussed to date.

## **Acknowledgements**

The authors thank the Portuguese Foundation for Science and Technology (FCT), European Union, QREN, FEDER and COMPETE for funding UnIC - Unidade de Investigação Cardiovascular (UIDB/00051/2020 and UIDP/00051/2020), iBiMED (UIDB/04501/2020, POCI-01-0145-FEDER-007628) and FCT LAQV/REQUIMTE (UIDB/50006/2020) research units. R.V. is supported by individual fellowship grants (IF/00286/2015). This work is funded by national funds (OE), through FCT Fundação para a Ciência e a Tecnologia , I.P., in the scope of the framework contract foreseen in the numbers 4, 5 and 6 of the article 23, of the Decree-Law 57/2016, of August 29, changed by Law 57/2017, of July 19.

*The Salivary Secretome DOI: http://dx.doi.org/10.5772/intechopen.98278*

## **Conflicts of interest**

The authors declare no conflicts of interest.

## **Author details**

Luís Perpétuo1 , Rita Ferreira<sup>2</sup> , Sofia Guedes2 , Francisco Amado2 and Rui Vitorino1,2,3\*

1 iBiMED, Department of Medical Sciences, University of Aveiro, Aveiro

2 LAQV/REQUIMTE, Department of Chemistry, University of Aveiro, Aveiro

3 Departamento de Cirurgia e Fisiologia, Faculdade de Medicina da Universidade do Porto, UnIC, Porto

\*Address all correspondence to<EMAIL_ADDRESS>
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## **References**

[1] Khurshid Z, Zohaib S, Najeeb S, Zafar MS, Slowey PD, Almas K. Human saliva collection devices for proteomics: an update. International journal of molecular sciences, 17(6), 846 (2016).

[2] Dawes C. Salivary flow patterns and the health of hard and soft oral tissues. The Journal of the American Dental Association, 139, 18S-24S (2008).

[3] Podzimek S, Vondrackova L, Duskova J, Janatova T, Broukal Z. Salivary markers for periodontal and general diseases. Disease markers, 2016 (2016).

[4] Khurshid Z, Zafar MS, Khan RS, Najeeb S, Slowey PD, Rehman IU. Role of salivary biomarkers in oral cancer detection. Advances in clinical chemistry, 86, 23-70 (2018).

[5] Abdul Rehman S, Khurshid Z, Hussain Niazi F et al. Role of salivary biomarkers in detection of cardiovascular diseases (CVD). Proteomes, 5(3), 21 (2017).

[6] Saitou M, Gaylord E, Xu E et al. Functional specialization of human salivary glands and origins of proteins intrinsic to human saliva. bioRxiv, 2020.2002.2012.945659 (2020).

[7] Feizi A, Gatto F, Uhlen M, Nielsen J. Human protein secretory pathway genes are expressed in a tissue-specific pattern to match processing demands of the secretome. npj Systems Biology and Applications, 3(1), 22 (2017).

[8] Chansaenroj A, Yodmuang S, Ferreira JN. Trends in salivary gland tissue engineering: from stem cells to secretome and organoid bioprinting. Tissue Engineering Part B: Reviews, (2020).

[9] Hassaneen M, Maron JL. Salivary diagnostics in pediatrics: applicability, translatability, and limitations. Frontiers in public health, 5, 83 (2017).

[10] Pappa E, Kousvelari E, Vastardis H. Saliva in the "Omics" era: A promising tool in paediatrics. Oral diseases, 25(1), 16-25 (2019).

[11] Khurshid Z, Zohaib S, Najeeb S, Zafar MS, Rehman R, Rehman IU. Advances of proteomic sciences in dentistry. International journal of molecular sciences, 17(5), 728 (2016).

[12] Rahim MAA, Rahim ZHA, Ahmad WAW, Hashim OH. Can saliva proteins be used to predict the onset of acute myocardial infarction among high-risk patients? International journal of medical sciences, 12(4), 329 (2015).

[13] Wang X, Kaczor-Urbanowicz KE, Wong DT. Salivary biomarkers in cancer detection. Medical Oncology, 34(1), 1-8 (2017).

[14] Roi A, Rusu LC, Roi CI, Luca RE, Boia S, Munteanu RI. A new approach for the diagnosis of systemic and oral diseases based on salivary biomolecules. Disease markers, 2019 (2019).

[15] Meinken J, Walker G, Cooper CR, Min XJ. MetazSecKB: the human and animal secretome and subcellular proteome knowledgebase. Database, 2015 (2015).

[16] Silberring J, Ciborowski P. Biomarker discovery and clinical proteomics. TrAC Trends in Analytical Chemistry, 29(2), 128-140 (2010).

[17] Wang A, Wang CP, Tu M, Wong DT. Oral biofluid biomarker research: current *The Salivary Secretome DOI: http://dx.doi.org/10.5772/intechopen.98278*

status and emerging frontiers. Diagnostics, 6(4), 45 (2016).

[18] Hsu C-W, Yu J-S, Peng P-H et al. Secretome profiling of primary cells reveals that THBS2 is a salivary biomarker of oral cavity squamous cell carcinoma. Journal of proteome research, 13(11), 4796-4807 (2014).

[19] Wei F, Wong D. Point-of-care platforms for salivary diagnostics. The Chinese journal of dental research: the official journal of the Scientific Section of the Chinese Stomatological Association (CSA), 15(1), 7-15 (2012).

[20] Soper SA, Brown K, Ellington A et al. Point-of-care biosensor systems for cancer diagnostics/prognostics. Biosensors and Bioelectronics, 21(10), 1932-1942 (2006).

[21] McRae MP, Simmons GW, Wong J et al. Programmable bio-nano-chip system: a flexible point-of-care platform for bioscience and clinical measurements. Lab on a Chip, 15(20), 4020-4031 (2015).

[22] Ngounou Wetie AG, Sokolowska I, Woods AG et al. Automated mass spectrometry–based functional assay for the routine analysis of the secretome. Journal of laboratory automation, 18(1), 19-29 (2013).

[23] Hosseini S, Espinosa-Hernandez MA, Garcia-Ramirez R, Cerda-Kipper AS, Reveles-Huizar S, Acosta-Soto L. BioMEMS.).

[24] Espinosa-Hernandez MA, Reveles-Huizar S, Hosseini S. Biomicroelectromechanical Systems (BioMEMS) in Bio-sensing Applications-Colorimetric Detection Strategies. In: BioMEMS. (Springer, 2021) 21-67.

[25] Naher S, Orpen D, Brabazon D, Morshed MM. An overview of

microfluidic mixing application. In: Advanced Materials Research. (Ed.^(Eds) (Trans Tech Publ, 2010) 931-939.

[26] Morris MC. Fluorescent biosensors probing protein kinase function in cancer and drug discovery. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 1834(7), 1387-1395 (2013).

[27] Mitchell AC, Alford SC, Hunter SA et al. Development of a protease biosensor based on a dimerizationdependent red fluorescent protein. ACS chemical biology, 13(1), 66-72 (2018).

[28] Tu M, Cheng J, Chen Y-L et al. Electric Field–Induced Release and Measurement (EFIRM): Characterization and Technical Validation of a Novel Liquid Biopsy Platform in Plasma and Saliva. The Journal of Molecular Diagnostics, 22(8), 1050-1062 (2020).

[29] Wei F, Strom CM, Cheng J et al. Electric field–induced release and measurement liquid biopsy for noninvasive early lung cancer assessment. The Journal of Molecular Diagnostics, 20(6), 738-742 (2018).

[30] Mani V, Beduk T, Khushaim W et al. Electrochemical sensors targeting salivary biomarkers: A comprehensive review. TrAC Trends in Analytical Chemistry, 116164 (2020).

[31] Goswami Y, Mishra R, Agrawal AP, Agrawal LA. Salivary biomarkers: A review of powerful diagnostic tool. IOSR J. Dental Med. Sci, 14(3), 80-87 (2015).

[32] Yoshizawa JM, Schafer CA, Schafer JJ, Farrell JJ, Paster BJ, Wong DT. Salivary biomarkers: toward future clinical and diagnostic utilities. Clinical microbiology reviews, 26(4), 781- 791 (2013).

[33] Gug IT, Tertis M, Hosu O, Cristea C. Salivary biomarkers detection: Analytical and immunological methods overview. TrAC Trends in Analytical Chemistry, 113, 301-316 (2019).

[34] Castagnola M, Scarano E, Passali G et al. Salivary biomarkers and proteomics: future diagnostic and clinical utilities. Acta Otorhinolaryngologica Italica, 37(2), 94 (2017).

[35] Sivadasan P, Gupta MK, Sathe GJ et al. Data from human salivary proteome–A resource of potential biomarkers for oral cancer. Data in brief, 4, 374-378 (2015).

[36] Proctor GB. The physiology of salivary secretion. Periodontology 2000, 70(1), 11-25 (2016).

[37] Keremi B, Beck A, Karoly Fabian T et al. Stress and salivary glands. Current pharmaceutical design, 23(27), 4057- 4065 (2017).

[38] Wang J, Liang Y, Wang Y et al. Computational prediction of human salivary proteins from blood circulation and application to diagnostic biomarker identification. PLoS One, 8(11), e80211 (2013).

[39] Caccia D, Dugo M, Callari M, Bongarzone I. Bioinformatics tools for secretome analysis. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 1834(11), 2442-2453 (2013).

[40] Ashburner M, Ball CA, Blake JA et al. Gene ontology: tool for the unification of biology. Nature genetics, 25(1), 25-29 (2000).

[41] Khatri P, Drăghici S. Ontological analysis of gene expression data: current tools, limitations, and open problems. Bioinformatics, 21(18), 3587- 3595 (2005).

[42] Szklarczyk D, Franceschini A, Kuhn M et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic acids research, 39(suppl\_1), D561-D568 (2010).

[43] Cline MS, Smoot M, Cerami E et al. Integration of biological networks and gene expression data using Cytoscape. Nature protocols, 2(10), 2366 (2007).

[44] Ma Z-Q, Tabb DL, Burden J et al. Supporting tool suite for production proteomics. Bioinformatics, 27(22), 3214-3215 (2011).

[45] Martens L, Chambers M, Sturm M et al. mzML—a community standard for mass spectrometry data. Molecular & Cellular Proteomics, 10(1), R110. 000133 (2011).

[46] Orchard S, Hermjakob H. The HUPO proteomics standards initiative—easing communication and minimizing data loss in a changing world. Briefings in bioinformatics, 9(2), 166-173 (2008).

[47] Deutsch EW, Lam H, Aebersold R. PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows. EMBO reports, 9(5), 429-434 (2008).

[48] Jones P, Martens L. Using the PRIDE proteomics identifications database for knowledge discovery and data analysis. In: Proteome Bioinformatics. (Springer, 2010) 297-307.

[49] Smith BE, Hill JA, Gjukich MA, Andrews PC. Tranche distributed repository and ProteomeCommons. org. In: Data Mining in Proteomics. (Springer, 2011) 123-145.

[50] Rehman AU, Olof Olsson P, Khan N, Khan K. Identification of Human Secretome and Membrane

*The Salivary Secretome DOI: http://dx.doi.org/10.5772/intechopen.98278*

Proteome-Based Cancer Biomarkers Utilizing Bioinformatics. The Journal of membrane biology, 253, 257-270 (2020).

[51] Shin J, Rhim J, Kwon Y et al. Comparative analysis of differentially secreted proteins in serum-free and serum-containing media by using BONCAT and pulsed SILAC. Scientific reports, 9(1), 1-12 (2019).

[52] Min XJ. Evaluation of computational methods for secreted protein prediction in different eukaryotes. JPB, 3(5) (2010).

[53] Uhlén M, Fagerberg L, Hallström BM et al. Tissue-based map of the human proteome. Science, 347(6220) (2015).

[54] Keerthikumar S. A catalogue of human secreted proteins and its implications. AIMS Biophys, 3(4), 563-570 (2016).

[55] Chen G, Chen J, Liu H et al. Comprehensive identification and characterization of human secretome based on integrative proteomic and transcriptomic data. Frontiers in cell and developmental biology, 7, 299 (2019).

[56] Mona M, Kobeissy F, Park Y-J et al. Secretome Analysis of Inductive Signals for BM-MSC Transdifferentiation into Salivary Gland Progenitors. International journal of molecular sciences, 21(23), 9055 (2020).

[57] Khan RS, Khurshid Z, Yahya Ibrahim Asiri F. Advancing point-of-care (PoC) testing using human saliva as liquid biopsy. Diagnostics, 7(3), 39 (2017).

## **Chapter 2** Endothelial Secretome

*Luiza Rusu*

## **Abstract**

Endothelial cells produce huge proteomes from a relatively small total number of ECs. The ECs' complex intercellular communication is possible through well-stored, classified, and compartmentalized secretory pathways, intermediated by the secretory vesicles and granules, with the purpose to maintain vascular homeostasis and integrity. Secreted proteins are involved in a myriad of cell communication processes. The local vascular microenvironment dynamically and constantly modifies the ECs' secretome. We focus on the biological significance of secretome proteins in a healthy vascular microenvironment and under cardiovascular conditions. Vascular ECs crosstalk with other ECs, and other blood cells at a distance, with the circulating hematopoietic stem cells permitting adequate reactions to vascular injury, systemic or local inflammation, and viral or parasitic infections. Here, we overview current secretome biomarkers in vascular diseases, with a focus on their roles in diagnostic, prognostic, and therapeutics. Also, we highlighted some important pathological effects of exosome on cardiovascular disease. This chapter discusses current research directions characterizing vascular pathology conditioned secretomes, their regulation, and therapeutic pursuit. The overall aim of this chapter is to review current literature updates on endothelial secretome roles in endothelial homeostasis and in vascular disorders.

**Keywords:** endothelial cells, secretome, Weibel–Palade bodies, extracellular vesicles, exosomes, signal transduction, intercellular crosstalk, secretory pathways, ectodomain shedding

## **1. Introduction**

Endothelium consists of approximately 1014 cells in all the vasculature [1]. Due to its versatile functions, the endothelium has been compared with a metabolic organ [1]. The ECs' secretomes comprise all proteins secreted outside the cell, including enzymes, growth factors, and hormones. ECs have the most diverse regulatory roles, starting with a mechanical barrier, vascular tone, hemostasis, and thrombosis (including control of platelet response), inflammation, vascular permeability, and angiogenesis. The interactions of ECs with leukocytes are also mediated by constituents of the ECs' secretome. The local microenvironment influences ECs' secretome output. For instance, the presence or absence of certain constituents in the secretory vesicles or granules can be selectively changed by local inflammation or by shear stress [2]. Endothelial cells produce huge proteomes from a relatively small total number of ECs. This is possible by well-stored, classified, and compartmentalized

polarized exocytosis [3]. Exchange information at a distance with other ECs, and with other blood cells, with the circulating hematopoietic stem cells. Vascular ECs crosstalk is intermediated by the secretory vesicles and granules with the purpose to maintain vascular homeostasis and integrity [4].

Despite the crucial role endothelial secretome is playing in EC function, we are only recently started to understand the molecular mechanisms governing the EC secretory function. In 2009, the first proteomic analysis on cultured HUVEC was conducted, and that study identified a number of 374 secreted proteins using nanoflow LC–MS/MS permitting the identification of angiogenic factors, extracellular matrix components, proteins involved in coagulation and inflammation, and in vascular tone, permeability and regeneration, and atherosclerosis and dissemination of metastasis [3]. More recently, 183 proteins were identified to be associated with the main secretory granules in quiescent HUVECS by proximity proteomics [5]. Meanwhile, a lot of progress was made in these regards, while some aspects are still under elucidation.

ECs intercellular crosstalk, which is mostly happening in the extracellular space, is highly controlled by ECs secretory pathways. It implies a donor (parent) cell which packs its contents into vesicles and a target (acceptor) cell that internalizes and uptake the vesicles. Endothelial cell secretory pathways occur via different size vesicles as follows: exocytosis of the principal secretory granules, Weibel–Palade bodies, and through smaller secretory granules, extracellular vesicles, and exosomes. Shedding of the ectodomain also provides many receptors and ligands for the target (recipient or acceptor) cell [6].

The main secretory storage granules of the ECs are Weibel–Palade bodies (WPBs), which represent the bulk source of stored, highly multimeric von Willebrand factor (vWF) [7]. The only other sources of vWF in the body are megakaryocytes and platelets α-granules, but they provide vWF in much smaller quantities only when stimulated [8]. WPBs are highly specialized organelles that ensure that ECs can promptly, and time-dependently respond to vascular injury or stress by enabling the controlled release of hemostasis and angiogenic factors, like vWF and not only to maintain vascular integrity. WPBs are large storage granules, their size ranges between 1 and 5 μm long and 100–300 nm wide, therefore, they are ideal for microscopy studies for secretion visualization from vascular endothelial cells.

Recent studies provide novel insights regarding endothelial secretome. Importantly, a recently published *proximity proteomics study* from Holthenrich et al. [5] provided interesting updates regarding *WPB secretion regulation factors and the endothelial secretome*.

EVs were first described in Peter Wolf as "platelet dust" and first characterized in 2011 by Gyorgy et al. [9] EVs are complex vesicular structures responsible for intercellular communication by transferring between cells: cytosolic proteins (e.g., enzymes and cytoskeletal proteins), lipids, mRNA, miRNA, and organelles from the parent cell.

EVs are released by virtually all cell types. EVs were identified in most body fluids and in the tissue matrix [10, 11]. Vesicles distinguish from one another based on size and density range and the mechanisms leading to their formation [12]. EVs originating from the cell membrane, by exposing to the exterior of the cytosolic side, by outward blebbing and budding, are named *microvesicles, ectosomes,* or *microparticles* [13, 14]. EVs that originate from the intracellular endocytic trafficking pathway is budding inward from the endosomal compartment, accumulate in multivesicular bodies (MVBs) in the form of many intraluminal vesicles [13] that upon fusion of the

limiting membrane of MVBs with the plasma membrane, are released as *exosomes* [9, 14, 15]. EC-derived EVs biogenesis is lipid rafts-dependent and ADP-ribosylation factor 6 (ARF6)-dependent [16].

Several regulator molecules localized simultaneously on the EVs surface, and on the EC acceptor cells are known to be implicated in the delivery of cargo and uptake into the target cell, including integrins and integrin-associated proteins, tetraspanins, T-cell immunoglobulin, and mucin domain-containing protein-4 (TIM4), and lectins and heparan sulfate proteoglycans [4]. Tim4 is a receptor for TIM1 and phosphatidylserine on apoptotic cells. Without Tim4, macrophages cannot phagocytose apoptotic cells. These molecular pairs convey cargo delivery specifically to the vascular recipient cells, although it is not entirely clear how these processes occur [4].

EVs transfer their cargo from the parent cell to the target cell by: (1) docking to the target cell, (2) internalization of the EVs, and intracellular sorting through one of the endocytotic pathways; a pool of internalized EVs by the acceptor (target) cells are sent via endosomal escape, and (3) transfer of the EV content to the acceptor cell [4]. This way EVs influence the phenotypic traits of the recipient cell. Importantly, the released exosomes conserve many transmembrane proteins from the parent ECs.

ECs release into the extracellular space diverse types of EC-derived lipid membranal bilayer-enclosed structures in response to cellular activation or apoptosis, these microparticles have ambivalent functions (both favorable and detrimental) in vascular homeostasis.

In all, the aim of this chapter is to review current literature updates on endothelial secretome's roles in endothelial homeostasis and in vascular disorders. We focus on the biological significance of secretome proteins in the vascular microenvironment in health and under different cardiovascular conditions. Secretome biomarkers in vascular diseases will be overviewed, with a focus on their roles in diagnostic, prognostic, and therapeutics. We highlight the important pathological effects of exosomes in cardiovascular disease. Most importantly, this chapter discusses vascular pathology conditioned secretomes, their regulation, and future therapeutic pursuit.

## **2. EC Secretome and exocytosis**

## **2.1 Weibel: palade bodies (WPBs)–History, biogenesis, mechanisms, and pathogenesis**

**Discovery of WPBs -** Edward Weibel and George Emil Palade were the first to describe WPBs in the early sixties by examining small arteries with a transmission electron microscope as "a hitherto unknown rod-shaped cytoplasmic component which consists of a bundle of fine tubules, enveloped by a tightly fitted membrane, was regularly found in endothelial cells of small arteries in various organs in rat and man." [17] In TEM transversal section, WPBs are electrono-dense tubules packed in parallel bundles encapsulated in a lipid membrane. The tubules inside WPBs have a diameter of circa 12 nm and appear to be surrounded by a dense matrix, and sometimes they have a hinge at the end of the organelle. After WPBs discovery, it took approximately 20 years until the discovery of the main WPBs components. WPBs is the best example of a secretory organelle whose formation is dictated by vWF, its main storage constituent. vWF is secreted in the form of ultra-large multimers in response to the multitude of stimuli that activate ECs. vWF-deficient mice do not form EC WPBs [18]. Reversely, overexpression of vWF in other cell types leads to the formation of WPB-like granules with similar morphology: rod-shaped and striated granules [19, 20].

**WPBs biogenesis -** vWF is synthesized in the rough endoplasmic reticulum as a sequence of precursor conserved domains, as follows: D1-D2-D′-D3-A1-A2-A3-D4-B1- B2-B3-C1-C2-CK [21]. Consequently, furin, a pH-dependent enzyme, cleaves down the D1-D2 domain (approximately 100 kDa and ~ 750 aa) during the trans-Golgi network (TGN) processing step [21]. The sequence starting from the domain D′ and up to the cysteine knot (CK) domain represents the mature vWF [21, 22]. As vWF passes through the Golgi complex, it suffers more processing. At the level of the TGN, the presence of vWF leads to the biogenesis of WPBs [21]. In the TGN, vWF dimers go through the process of multimerization by bridging the D3 domains via interchain N-terminal disulfide bonds [22, 23]. In the TGN, WPBs go through a process of maturation and are directed, when needed, toward the basolateral surface in small vesicles [24] or stored in the highly multimerized form in WPBs [24] for later use via regulated secretion [21]. WPBs that protrude from the TGN have clathrin/AP1 coats on [25]. Overexpression of the dominant-negative construct AP180 and AP-1 inhibition with siRNA inhibits the formation of the clathrin coat. Therefore, it is considered that clathrin/AP1 are essential in the formation of vWF tubules and for their correct packaging [25]. Aftiphilin and ỿ-synergin are the downstream effectors of AP-1, which are recruited to the WPBs, as shown by their fluorescence microscopical partial colocalization with immature WPBs situated perinuclearly. Their depletion with siRNA does not modify the total number of WPBs or their intracellular distribution, but it increased the basal secretion of vWF and reduces the regulated vWF secretion [26]. vWF propeptide is necessary for WPBs biogenesis [20]. The vWF tubules are only forming at the level of TGN, not before, in the Golgi complex [25]. Immature (perinuclear) WPBs have different membrane protein sets than mature (cytoplasmic) WPBs. Upon maturation of WPBs, they lose their clathrin/AP-1 coat and its effectors aftiphilin and synergin [25, 26]. The tetraspanin CD63 is recruited to the mature WPBs with the help of the adaptor AP3, which targets proteins from endosome to the lysosome and related organelles. Lysosomal organelles, such as melanosomes and α-granules, have the characteristic to sort endosomal proteins into secretory granules after Golgi processing [27]. After the processing and maturation process, WPBs can be stored in the ECs for long times, for a few days [28].

**WPBs exocytosis -** vWF released from WPBs of vascular ECs has a crucial function in hemostasis and thrombosis. Under physiological conditions, WPBs have a low rate of basal secretion into the bloodstream that is thought to be required to maintain the blood level of VWF. The blood level of vWF is thought to be originating from the ECs exclusively, while the platelet α-granules and readily formed WPBs can supplement vWF released upon platelet activation. Under stimulation, the rate of WPBs can be rapidly increased by Ca2+- or by a cAMP-induced secretory mechanism. Upon activation of ECs, highly multimeric vWF is liberated from WPBs through the apical side of EC toward the bloodstream. Activated ECs lead to the regulated exocytosis of WPBs. As vWF is liberated from WPBs, it unfurls into long (1–5 μm) "strings" that platelets recognize via the A1 domain of vWF as "beads on the string" to initiate platelet adhesion and aggregation and the formation of a thrombus plug. Moreover, it vehiculated the idea that the contents of WPBs can be specifically altered, depending on where in the vasculature bed of which organs are ECs located. Ca2+ and cAMPdependent controlled WPBs exocytosis regulate the local vascular environment to mediate the interconnected processes of hemostasis, vascular inflammation, and thrombosis. The molecular mechanisms controlling the trafficking of ECs secretory

granules were only partially elucidated. We know that WPB priming and exocytosis are mediated by the N-ethylmaleimide factor, α-SNARE adaptor protein (α-SNAP), and SNARE receptors. WPB exocytosis depends on syntaxin 4, members of the SNARE complexes, synaptobrevin 3, synaptotagmin, and a sensor for Ca2 + −mediated exocytosis. In addition, nitric oxide (NO) was found to influence negatively NSF function by S-nitrosylation and inhibiting ECs exocytosis of vWF [29].

In addition, Weibel–Palade bodies contain P-selectin, other selectins, Rab27a, endothelin-1, endothelin-converting enzyme, angiopoietin, CD63, tissue-type plasminogen activator (tPA), interleukins (IL) IL-1, IL-8, CCL-2, eotaxin-3, osteoprotegerin, and calcitonin-gene related protein [30]. The question of cytokines incorporation into WPBs was recently revisited, Il1 and IL8 were found in WPBs but other cytokines are transported via other vesicles. These other components of WPBs like P-selectin, cytokines, and osteoprotegerin are incorporated during the processing phase in the TGN. P-selectin is a transmembranar protein, which is highly relevant for leukocyte rolling. Its big luminal domain is sufficient for the incorporation of P-selectin into the WPBs, even if truncated, probably because of its interaction with D′ and D3 domains of vWF [31, 32]. P-selectin is produced and stored in WPBs and the α-granules of platelets. P-selectin affects the formation of WPBs, andthe recruitment of leukocytes in vWF-deficient animals [33, 34].

**The secretome of WPBs** is characterized by dynamics and plasticity to meet the versatility of ECs pathophysiology [30]. Clotting factor VIII is stored in pulmonary ECs in association with vWF [35]. Osteoprotegerin is also stored in WPBs and its incorporation in WPBs is related to its interaction with vWF [7]. Osteoprotegerin (OPG) is one of the tumor necrosis factors (TNF) cytokine receptors [36]. Osteoprotegerin is involved in the inhibition of bone regeneration via OPG/the receptor activator of nuclear factor kappa-B (RANK)/receptor activator of nuclear factor kappa-B ligand (RANKL) axis, by decreasing the production of osteoclasts [36]. Another study focused on WPB resident proteins identified IGFBP7 by proteomic screening [7]. Angiopoietin-2 is part of a family of four growth factors whose activity is mediated via tyrosine kinase receptors (Tie) receptors 1 and 2. Angiopoietin-2 has different functions depending on the microenvironment conditions, an autocrine regulator, and an antagonist of Tie2. In activated ECs, vascular endothelial growth factor (VEGF) stimulation of angiopoietin-2 has proinflammatory effects. Angiopoietin-2 is incorporated into WPBs, at the level of TGN, if there is no P-selectin present because these two factors are mutually exclusive [37]. Angiopoietin-2 expression is induced by local inflammatory and prothrombotic factors, such as thrombin or under hypoxic conditions, and its release is highly regulated.

A recent study employed a new approach involving **proximity proteomics** to find proteins residing on the cytosolic face of the WPBs or in the vicinity of the organelle. In this case, biotinylating the target proteins in living cultured HUVECs followed by streptavidin pulldown and identification of the new proteins by tandem mass spectrometry [5]. The small GTPases Rab3b and Rab27 were previously identified in the proximity of WPBs on the cytoplasmic face of WPBs. In this study, the authors show that the two mentioned Rab small GTPases fused with peroxidase APEX2, and modified ascorbate peroxidase [5]. In this study, HUVECs were transfected with Rab3b tagged with FLAG-APEX2 construct. The resulted proteins were immunoblotted with anti-FLAG antibodies. Proteins associated with WPBs that were tagged, and upon adding biotin-phenol and peroxide of hydrogen for 1 minute there was peroxidasecatalyzed biotinylation of the protein in the vicinity of WPBs as shown by streptavidin pulldown from the pretreated HUVECs under resting conditions. The pulldowns were sent to tandem mass spectrometry.

This approach led to the identification of a total number of 183 proteins associated with WPBs and with one of the two Rab GTPases or with both constructs. Many of those were not identified in the vicinity or in association with WPB before. Importantly, these proteins were previously found to be related to membrane/ protein transport or to organelle dynamics and plasticity. Vacuolar ATPase ATP6V, syntaxin binding protein 1, Rab 46, phospholipase D1, GBF1, and phosphatidylinositol 4-kinase were identified as WPBs constituents, some of them were previously known to be related to WPBs exocytosis [5]. Rab 7, one of the proteins identified by proximity proteomics was thought to regulate the transport from endosome to WPBs [5]. Some Golgin family members were also identified by the same approach. The secretory pathway Ca 2+ ATPase type 1 is another newly discovered constituent of WPBs, which is known to be involved in Ca2+ homeostasis [5]. The fact that well-known markers of WPBs, such as P-selectin, VAMP-3, CD63, MyRIP, and Slp4a, were recognized in this study verifies the specificity of their approach. A previous study showed that the interplay between Rab27A and its effectors Slp-4 and MyRIP controls histamine-induced vWF secretion [38]. CD63 is well known to be associated with WPBs.

Importantly, one new protein associated with WPBs by proximity ligation is the priming/tethering factor Munc 13-2, which is a positive regulator of histamineinduced WPB exocytosis of vWF [5]. Munc 13-2 was previously implicated in WPB exocytosis of angiopoietin-2 from the brain ECs [39]. After the initial proteomic screening and verification, Munc 13-2 localizes at WPB surface, and they also demonstrated that Munc 13-2 siRNA affects histamine-induced vWF secretion [5]. In addition, Munc 13-2 cooperates with Munc 13-4, which was found to be a plasma membrane priming and fusion factor for evoked WPBs exocytosis [5].

**WPBs defects -** Defects in the structure, packing, or sorting of vWF lead to von Willebrand disease (vWD), which has an incidence of approximately 1:1000 in general population and represents the most common inherited coagulopathy in humans. The inherited defects in vWF result in smaller and defective WPBs. Defects in the proteins that regulate WPB exocytosis also led to vWD. Reversely, excess of vWF released by activated ECs exposed to high shear stress or to vascular inflammation, or infection tilts the thrombotic propensity leading to disseminated intravascular coagulation and microvascular thrombosis.

## **2.2 Secretory granules, vesicles of 100–500 nm diameter which store cargo of smaller dimensions**

The initial belief that cytokines reside exclusively in WPBs in vascular ECs from where they are released upon stimulation, that is, with histamine, was recently challenged [40]. The question of cytokines incorporation into WPBs was recently revisited, Il-1 and IL-8 were found in WPBs but other cytokines are transported via other vesicles. It was proven that cytokines originate and are also secreted from smaller vesicles by vascular ECs and that cytokines (monocyte-chemoattractant protein-1 [MCP-1], IL-6, and IL-8), EGFP, and tissue plasminogen (tPA) are much less efficiently stored in WPBs compared with vWF, but are present in "tPA and type 2 organelles." [40] Chemokines are small cytokines that direct the movement of cells during embryogenesis, in order to maintain homeostasis or in pathological conditions. Their roles include cell proliferation, cell migration, cell differentiation,

### *Endothelial Secretome DOI: http://dx.doi.org/10.5772/intechopen.106550*

and implicit maintaining tissue and organs homeostasis by regulating the types and number of each cell produced. ECs express cytokines, such as interleukins (IL) IL-1, IL-5, IL-6, IL-8, IL-11, and IL-15, granulocyte/macrophage colony-stimulating factor (GM-CSF). Upon local or systemic vascular inflammation, secretion of a particular set of cytokines can attract specifically certain subtypes of leukocytes. ECs secrete chemokines, such as CCL2 (attracts monocytes), CCL5 (monocytes, eosinophils, and T cells), eotaxin-3/CCL26 (eosinophils), CXCL1 (to attract neutrophils), and CXCL10 (for T cells) [41–43]. Activated ECs secrete upon vascular injury by other coagulation agents, such as plasminogen activator inhibitor-1 (PAI-1) or other growth hormones like TGF-β [42].

Much of the intercellular communication performed by vascular ECs is done by means of soluble cytokines and chemokines. Upon endothelial cell activation during inflammation, cytokines are released from EC secretory vesicles, and there is vasodilation to lower the blood flow and recruitment of leukocytes at the site of infection or injury. The first step is the vasodilation of the blood vessel, which allows for better leukocytes interaction with the vascular ECs. Vasodilatation is partly a result of EC-induced mechanisms. The endothelium secretes increased the level of P- and E-selectins, intracellular adhesion molecules (ICAM), and integrins. 1) **rolling adhesion**: The initial low-affinity endothelial-leukocyte interactions involve an increased level of selectins. P-selectin is secreted from WPBs in minutes, in response to histamine released by mast cells or mediated by TNF-α or LPS. TNF-α is one type of molecule produced by macrophages in response to pathogen detection, causing endothelial activation. Histamine-mediated activated ECs rapidly externalize WPBs content, which includes preformed P-selectin. TNF-α or LPS induce the synthesis of E-selectin, which is exposed to the cell surface a few hours later. Selectins recognize Sialyl-LewisX on the rolling leukocytes across the endothelium, allowing them to adhere reversibly (tethering or capture) to the vascular wall. Without these initial interactions, the next steps of chemokine-dependent and chemokine-independent mechanisms leukocyte activation, and extravasation would not occur. These steps depend on the production and adequate release of P-selectins from WPB granules of vascular ECs. 2) **Leukocyte-Endothelial tight binding** relies on integrins (VLA-4, CD18, and CD11) on leukocytes and ICAMs on the surface of vascular ECs, such as TNF-α-induced endothelial ICAM-1, or ICAM-2, and VCAM-1 3, **diapedesis** is the step in which the leukocyte extravasate the endothelial wall. This step involves the interaction of integrins (CD11/CD18 and VLA-4) on leukocytes with ICAMs on ECs (i.e., ICAM-1 and VCAM-1), and with PECAM-1 (CD31).

## **2.3 Secretome trafficking via extracellular vesicles (EVs)**

## *2.3.1 Secretome trafficking via endothelial microvesicles (MVs)*

Endothelial MVs are plasma membrane-derived vesicles, they occur through blebbing and budding of the cell membrane starting intracellularly from the cytosol, budding toward the exterior of the cell [12]. Their size ranges from 100 to 2000 nm [15]. The majority of MVs come from platelets. Vesicles should be collected from plasma not from serum because activation of platelets leads to excessive release of platelets MVs, and contamination of the sample.

### *Periodontology - New Insights*

EVs reflect the status of the patent cell. EC-derived EVs can be released with the purpose to protect the endothelium from distress, therefore, they fulfill the function of gatekeepers, with cytoprotective and antiapoptotic effects.

One of the factors known to regulate the biogenesis of the microparticles is ARF6 [16].

EC-derived MVs carry markers/regulator proteins that are associated with a pathological state: vascular endothelial cadherin (VE-cadherin), endoglin (CD105), (c-Src kinase+, eNOS+ and caveolin1+, EPCR+). ECs-derived MVs from plasma of septic mice had increased levels of VE-cadherin+ and endoglin+ vesicles compared to sham control. EC-derived MVs applied *in vitro* on cultured ECs cause endothelial permeability dysfunctions by disturbing the adherens junctions and the cytoskeleton [44]. Platelet endothelial cell adhesion molecule-1 (CD31+ or PECAM-1), E-selectin, αv integrin (CD51), and intercellular cell adhesion molecule (ICAM)-1 (cytokine-stimulated HUVECs released increased levels of both factors; moreover, E-selectin-targeting to inflamed ECs help delivery of miRNAs from MVs, with anti-inflammatory effects [45]), or S-endo (CD146) [45], endothelial NO synthase, oxidated negatively charged phospholipids (infusion with man-made negatively charged phospholipid vesicles leads to severe thrombosis in primates and murine models [46]), and vascular endothelial growth factor receptor (VEGF-R2) [47]. High adhesion molecules level constitute a sign of endothelial dysfunction and decreased vessel elasticity [46].

Because the presence of EVs released by ECs in the circulation usually indicates a vascular or systemic disease, they can be used as markers of endothelial dysfunction. The endothelial origin of circulating MVs can be established by flow cytometry and other laboratory tests. One caveat is that, apart from E-selectin and VE-cadherin, these protein markers are not expressed exclusively by the vascular cells.

In the case of transfer of membrane-bound MVs by cocultures, recipient cells take some phenotypic characteristics of the MV-producing cells; sick or degenerative cell regain their normal phenotype, and a bidirectional membrane transfer is observed between cells. Circulating EVs can be distinguished by tissue source and disease state profiling. EVs are molecular heterogeneous and overlap a lot. There is also large heterogeneity in the mechanical properties of EVs that may dictate cellular behavior.

### *2.3.2 Secretome trafficking through exosomes*

Exosomes are nanoscale vesicles with a diameter ranging between 30 and 150 nm. Exosomes can be released from any type of cell in the body, their release is higher from certain cell types. Exosomes originate from the intracellular endocytic trafficking pathway, during the endosome compartment maturation in MVBs; MVBs membrane fusion with the cell membrane allows the release of their intraluminal vesicle as exosomes, as shown by electron microscopic shots of exosomes that previously endocytosed colloidal gold [15].

Exosome biogenesis involves a two-step budding process: step 1) inward budding of the external plasma membrane through the endocytotic pathway to the endosomal compartment and intraluminal vesicles into MVBs and step 2) cytosolic MVBs secrete the exosome cargo. Importantly, the released exosomes conserve many transmembrane proteins from the parent ECs.

Silencing the endosomal sorting complex transport protein (ESCRT) members, ESCRT-0 and/or ESCRT-I, decreases exosome secretion [48], and modified the size of exosomes and their composition, and major histocompatibility complexes (MHC)

### *Endothelial Secretome DOI: http://dx.doi.org/10.5772/intechopen.106550*

levels, especially, impaired MHC II content, as shown by immunogold electron microscopy [48].

Several proteins are involved in exosome cargo sorting. Small GTPases Rab7a and Rab27b, found mainly on late endosomes, coordinate miRNA 143/miRNA150 export through nanovesicular trafficking, in response to the shear stress-inducible transcription factor Krüppel-like factor 2 (KLF2) overexpression, in cultured HUVECs, to levels that mimic shear stress levels [49]. The release of the exosome cargo goes through a Rab11- and Rab35-dependent regulatory pathway, which is involved in slow endocytic endosome recycling [49].

ShRNA knockdown of ESCRT-associated proteins, VTA, TSG101, VPS4, and ALG-2-interacting protein X increased exosome secretion, and increased MHC II proteic and mRNA content, as demonstrated on a 96-well plate screen of over 20 components of the ESCRT system and associated proteins [48].

Exosomes are characterized by: 1) expression of a set of integrins and tetraspanins (CD9, CD63, CD81, and CD82) for targeting and adhesion, 2) expression of proteins involved in membrane transport and fusion (annexins, Rab proteins, and flotillin), 3) expression of proteins associated with multivesicular body biogenesis (ALG-2-interacting protein X, TSG101, VPS4,a and VTA), 4) lipid-rafts (sphingolipids, sphingomyelinase, lipid ceramide, and cholesterol), 5) heat shock protein (HSP)-70 and − 90, as well as of 6) MHC I and II. 7) Another specific exosomal marker is a lysosomal-associated membrane protein-1 (Lamp1). 8) Importantly, EC-derived EVs contain miRNAs conveying immune responses.

Exosomes can be visualized on a NanoSight microscope. The uptake of endothelial exosomes, and the gain of function exosomes transfer can be measured.

Published data show that EC exosomes secreted in the circulation influence cellular behavior via paracrine signaling and can have huge biopotential: exosomes influence cell phenotypes, regulate protein synthesis, convey immune responses, stimulate angiogenesis, endothelial proliferation and migration, cell-free regeneration potential, and cardioprotective effects.

### *2.3.3 Caveolae*

ECs also contain many caveolae, specialized endocytosis structures which are necessary for transcytosis of a variety of substances (i.e., albumin transport [5, 37] across the EC layer).

## *2.3.4 Tunneling nanotubules*

Endothelial cells communicate with the help of tunneling nanotubes (TNT), which can be up to or more than 100 μm long and 50–200 nm in diameter. TNTs are composed of open-ended F-actin, nonadherent. TNTs form transiently for 30 minutes to 2 h and then retract and disappear.

### **2.4 Shedding of protein Ectodomains**

Apart from the classical secretory pathways, about 2–4% of cell membrane proteins are released in circulation or into the extracellular space, in health or under pathological conditions, by *ectodomain shedding,* which is a proteolytic removal of a significant portion of the transmembrane protein ectodomain (the extracellular domain) [6]. Ectodomain shedding is relevant in growth factor signaling to cell

adhesion, inflammation, cell survival, and cancer. The results of ectodomain shedding for ECs differ strongly depending on the type of shed transmembranar protein (i.e., adhesion molecules, growth factors, cytokines, and cell receptors). The shed enzymes are **membrane-bound proteolytic enzymes that cleave**, releasing the soluble ectodomains and leaving behind a protein fragment bound to the plasma membrane that can initiate signaling at this level or can be internalized in membranebound vesicles for unusual destination signaling in the nucleus to target gene activity or in the mitochondria.

ADAM17 and ADAM10 metalloproteases are the main sheddases expressed by ECs from the "a disintegrin and metalloprotease" (ADAM) family of sheddases. Upon inflammation, ADAM10 is responsible through a notch-dependent regulation for DII-1 and -4 expression and changes in Hes1 and Hey1 expression.

Among over 40 shedding substrates that ADAM10 has on resting and/or activated ECs, the most important ones include as follows: IL-6, Interleukin-6-receptor (IL-6R), IL-8 [50], CX3CL1, CD44, CXCL16, MCP-1, VEGFR2, sVCAM1 (on TNFactivated ECs) [51]. DLL4 and VE-cadherin (regulates endothelial permeability and transmigration [51–54].

## **2.5 Organotypic EC secretome**

Location dictates the function; it was demonstrated over the years that the characteristics of the secretome of different subtypes of ECs are dependent on their localization in the vasculature bed. Distinct subtypes of ECS secrete tissuespecific proteomes, which regulate specifically tissue homeostasis and regeneration and functional pathophysiology. There are key features specific to the secretome of the continuous, discontinuous, fenestrated, sinusoidal, Schlemm's canal specialized ECs, and high endothelial venules. Brain, retina, and bones have organotypically differentiated ECs with specific morphological features that predict the functional particularities specific to the vessel bed and the tissue-specific EC secretome. Under physiological conditions, ECs have quiescent functions and phenotypic characteristics and they produce a different sets of vesicles and granules constituents upon activation. Quiescent ECs are not inactive though but under normal conditions they are inactive. They function as a gatekeeper in their microenvironment to control tissue function, homeostasis, and regeneration. As gatekeepers, ECs respond to different stimuli (inflammatory, infectious, metastasis, and high shear stress), they modify accordingly their phenotypes and functions to preserve vascular homeostasis. The molecular mechanisms controlling ECs vessel-bed specific differentiation and function are now emerging for protein preparation and secretion, and protein export into the extracellular microenvironment.

## **2.6 ECs apical and basolateral secretome**

Endothelial cells have distinctive apical and basolateral secretomes. ECs polarize the secretion of small vesicles toward the apical side of ECs. For example, cytokines that are destined for blood circulation are secreted into the apical side of ECs. In contrast, the basolateral proteome is destined toward the components of the extracellular matrix, sharing their route with fibronectin and liprin-α1. The approach employed to dissect protein sorting in ECs to basolateral or apical compartments was to grow

HUVECs on transwell inserts with separate collecting compartments for basolateral and for the apical secretory pathways.

### **2.7 miRNAs transfer functionally using EVs**

A microRNA is RNA that binds with imperfect complementarity to its target mRNA, might be 6–7 nucleotides long sequences, with a lot of opportunities for binding at the end of the target mRNA, and many non-canonical mechanisms were described so far. The difference between siRNA (which was described first) and miRNA is the degree of complementarity with the target. miRNA bind to its target leads to shutting down of translation by several mechanisms: translational inhibition, deadenylation, and cleavage in certain situations. At the heart of the miRNA mechanism is arg0naute protein (Ago), which is part of the miRNA-mediated gene silencing complex (RISC). miRNA is loaded with the argonaute as it is made, mature acts as part of argonaute RISC complex.

Rab GTPases regulate membrane trafficking for EC-derived vesicular miRNA [49]. In cultured ECs, the miR-143 vesicular export occurs through a Rab7a/Rab27bdependent mechanism, induced by overexpression of the transcription factor KLF2 at levels that mimic high shear stress [49].

## **3. Role of endothelial Secretome in endothelial dysfunction**

Dynamic vasculature regulation correlates (updates) ECs secretome with ECs functional needs in health, and under inflammatory conditions, under high shear stress, or under abnormal angiogenic factors.

Upon injury, cells are recruited by exosome-mediated receptor-mediated interactions, variety of responses occur in the vasculature because of the diverse mechanisms of action. Internalization of EC exosomes by monocytes/macrophages can suppress systemic inflammation. In open wounds, exosome secretion of cytokine influences the cellular behavior of fibroblasts toward wound healing.

In pulmonary arterial hypertension (PAH), depletion of pulmonary caveolin-1 from the lungs is partially due to caveolin-1 positive extracellular vesicle (bigger than 100 nm) blebbing and shedding into the circulation [55]. Elevated levels of blood caveolin-1 + EVs correlated with TGF-β-induced microvascular remodeling and PAH [55]. In PAH, the vascular injury most probably induces EV release and caveolin-1 depletion from pulmonary ECs, while the "second hit" that promotes vascular remodeling might be chronic hypoxia [55]. In acute lung injury (ALI), EVs released by vascular ECs and epithelial cells in the lung has been shown to mediate cell-to-cell communication and transport bioactive molecules between cells. However, the role of bioactive proteins and lipid mediators carried by EVs in ALI pathophysiology is explored insufficiently. Mouse bronchoalveolar lavage fluid-derived EVs were found to contain high levels of cyclooxygenase, lipoxygenase, and cytochrome p450 metabolites, those levels increase during the acute inflammatory phase and decrease in the resolution phase of LPS-induced ALI.

*Exosomes derived from apoptotic ECs* have a particular secretome output, they contain self-made, self-tailored, non-coding RNAs and are *highly immunogenic*. Apoptotic ECs exosomes are carrying RNAs that are not usually found in healthy cells: viral-like endogenous retroelements (those are the most abundant), mitochondrial

RNAs, U1 small nuclear RNA, and Y RNA that are involved in autoimmunity responses [56]. These nucleic acids are rich in U-bases and unstable folded, self-made RNAs of endothelial cells in apoptosis that can be recognized by toll-like receptors (TLR3, 7, and 8). They encompass a demonstrated role in murine models of inflammation and innate immune responses [56].

MiRNA-enriched EVs derived from monocytes can be transfer to quiescent, unstimulated ECs, which enhanced EC permeability and monocyte transmigration in a co-culture system condition.

In an *in vitro* study, Li et al. employed a co-culture system in which neutrophils extracted from healthy donor blood were co-cultured with brain microvascular ECs in presence of LPS. Exosomes purified from the LPS- exposed miR-122-5p rich neutrophils regulate oxidative stress, permeability, or apoptosis of capillary ECs in the brain [57].

miRNA-containing EVs originating from activated or apoptotic EC are able to communicate to their neighbors, are protecting the adjacent vascular ECs from apoptosis, and have potent *anti-inflammatory effects* [58]. Endothelial MVs transporting miR222 to the neighboring ECs are significantly reducing the ICAM-1 level in proximity cells, which have impaired monocyte adhesion assay [59]. *In vitro*, the pretreatment with EC-derived EVs (obtained from ECs stimulated with TNF-α) lead to reduced endothelial ICAM-1 expression at mRNA and protein levels, while did not influence VCAM1 [59]. *In vivo*, they were also able to demonstrate reduced ICAM-1 expression in APO E−/−mice, as shown by immunostaining assays of fragments of descending aorta from APO E−/−mice [59]. These protective effects of EC-derived EVs occurred by delivery of miRNA-222 to recipient endothelial cells [59]. The efficient delivery of miRNA-222 to the recipient cells was demonstrated by employing an assay developed from C. elegans, HCAEC were transfected with cel-miR-39 [59]. Next, they applied prediction methods questioning the target mRNA for miRNA222, and the most probable target was found by ICAM1 [59]. By using inhibitors of miRNA222 they were able to verify that functional miRNA222 targets ICAM1 and reduces its mRNA and protein expression in cultured cells [59, 60].

In an unstimulated, quiescent state, vascular ECs secrete extracellular vesicles containing anti-inflammatory microRNAs [57, 61]. They are transferring miRNA to monocytes and other vascular cells to prevent monocyte activation [62].

EC-derived EVs that can transfer MiR-10a to monocytic/macrophagic cells have anti-inflammatory effects. They inhibit the proinflammatory phenotype by inhibiting many proinflammatory genes by repressing the induction of the nuclear factor-kB (NF-kB) and IRF5 transcriptional pathways. MiR-10a negatively regulates effector proteins that destabilize I-kB. EC-derived EVs that can transfer MiR-10a to monocytic/macrophagic cells suppress a network of genes. One of these genes is interleukin-1-receptor-associated-kinase-4 (IRAK4) gene, which acts upstream of NF-kB signaling. MiR-10a suppressed β-TRC, and MAP3K7/TAK1 [62]. Loss of miR10 during atherogenesis has the opposite effect of activation of monocytes [63].

Increased/disturbed shear flow may lead ECs to deliver miRNAs miR126-3p, miR200a-3p to target cells like smooth muscle cells (SMC) by means *independent of membrane-bound vesicles* and argonaute-2-dependent, which is protecting miRNAs during delivery to the target cells [64] via VAMP-3/SNAP23-mediated pathway, leading to SMC hyperplasia.

Endothelial cell-specific MiR-126 decreased inflammatory-inducible expression of adhesion molecules in ECs, it decreased TNFα-induced VCAM-1 level in cultured primary human ECs, respectively, as shown by immunoblotting [65]. The presence

### *Endothelial Secretome DOI: http://dx.doi.org/10.5772/intechopen.106550*

of proinflammatory cytokines, such as TNF-a, induce the expression of VCAM-1 through the induction of NFkB and IRF1 pathway [65]. It has been suggested that miR126 is a target for VCAM-1 gene because of partial sequence matching in the 3' UTR region position 619 to 625 within the human VCAM-1 transcript [65]. Transfection of HUVECs with antisense miR126 increased TNFα-induced VCAM-1 expression [65]. Overexpression of premiR-126, a precursor of miR126 increased endogenous miR126 and reduced VCAM1 expression [65]. Endothelial cell-specific MiR-126 negatively regulates leukocyte trafficking and adherence to TNF-αactivated HUVECs, through VCAM-1 expression inhibition [65]; the leukocyte rolling is VCAM-1 dependent, as shown by blocking VCAM-1 with an anti-VCAM-1 antibody [65, 66].

Primary rat hepatocyte-derived, CD81 and CD63 positive EVs were found to contain argininase-1, an enzyme that regulates the level of arginine, the substrate for eNOS nitric oxide synthetase [67, 68]. *In vivo*, these hepatic EVs obtained from the serum of rats under liver-damaging conditions with acetaminophen, or diclofenac treatment encapsulate more arginase-1 compared to untreated control [67], as shown by the untargeted blood metabolome approach [68]. Exposure of rat pulmonary artery ECs to hepatic EVs for 2 h provoked changes in ECs metabolome as compared to untreated control EVs, via an arginase-1-dependent mechanism [67]. Increased arginase activity led to nitric oxide defective synthesis and activity and ECs malfunction of pulmonary arteries in rats treated with liver-damaging drugs [67].

A screening (Taqman miRNA assay) for high levels of miRNAs in circulating vesicles collected from 180 patients with chronic coronary disease and circa 60 patients with the acute coronary syndrome, identified miRNA-92a-3p to be selectively increased in circulating vesicles isolated from plasma of patients with the coronary disease compared with control, as seen by RT-PCR [69], showing how atherosclerotic conditions selectively promote packaging of miRNAs, such as miRNA-92a-3p into circulating EVs [69]. The authors further explored the role of circulating vesicles carrying miRNAs on vascular ECs [69]. Functional miRNA-92a-3p was transferred from circulating vesicles into acceptor ECs [69]. MiR-92a-3p target is thrombospondin-1, which is increasing cell proliferation and migration, and inhibited angiogenesis and vessel-like networks [69].

Weilner et al. observed a higher rate of exosome secretion in senescent humans ECs compared with quiescent cells [70]. Circulating miR-31, encapsulated by senescent human EC-derived EVs, is upregulated in elderly donors and osteoporosis patients [70]. MiR-31-rich EV transfer in human mesenchymal stem cells inhibiting their differentiation toward osteogenesis, a switch from osteoblast genesis to osteoclast formation, which modifies the bone density [70]. Endothelial exosomes can transfer miR-503 to tumor cells, tumor cells can exert an antitumor effect via the transfer of miRNA from ECs, leading to decreased tumor growth and invasion [70].

## **4. Role of endothelial Secretome in vascular repair**

EVs from ischemic tissues play a role in endothelial cell survival and in *de novo,* angiogenesis as shown in a murine model of ischemia after femoral artery ligation [47, 71]. Hussein et al. showed that injured ECs release caspase 3-rich EVs to protect the endothelial cells from complement-induced apoptosis in cultured HUVECs. Conversely, in the presence of inhibitors like staurosporine they showed that caspase 3 levels increase [71]. Thus, endothelial-derived MV contributes to the elimination of excess, stress levels of apoptotic agents, and to avoid apoptosis and cellular detachment [71].

Endothelial cells react to stressful conditions by releasing EVs, as a form of communicating the distress to the cells in proximity and to protect the endothelium [46]. Under lipid-induced oxidative stress conditions, endothelial cells release EVs containing endothelial NO synthase via AKT/eNOS -dependent signaling pathway, to protect the vessel from endothelial damage [46].

Secretory granules and vesicles can release mediators that are directly involved in the gatekeeper actions of EC by immediate, basal, or by evoked, rapid secretion according to the functional needs of the ECs. CD47 is an integrin-associated protein found often on EVs. CD47 role is to prevent EVs phagocytosis by macrophages, therefore, increasing EVs circulation time [15]. Moreover, activated protein-C (APC) interacts with endothelial protein-C receptor (EPCR) exposed both on the MVs surface and on ECs can cleave PAR-1 and trigger signaling leading to activation of S1P1 which via PI3 and AKT-dependent transactivation of KDR stimulate cell proliferation, and ultimately has an endothelial barrier and cytoprotective effects [72].

Endothelial-derived MV contributes to the sorting of several proapoptotic factors preventing cell detachment and apoptosis [71]. MVs carrying APC induced cytoprotective effects in a staurosporine-induced endothelial cell model of apoptosis assessed by APOPercentage assay and improved EC permeability percentage [72]. Activated protein-C (APC) binding to endothelial protein-C receptor (EPCR) exposed both on the MVs surface and on ECs can cleave PAR-1 and trigger signaling leading to activation of S1P1 which via PI3 and AKT-dependent transactivation of KDR, which, in turn, stimulate cell proliferation, with endothelial barrier protective and EC survival effects [72].

Endothelial exosomes are thought to be involved in angiogenesis. They incorporate and transfer delta-like-4 (Dll4), a notch ligand upregulated during angiogenesis, to neighboring endothelial cells via EVs, beyond cell–cell contact, conferring a tip cell phenotype to the detriment of stalk cells, resulting in a low level of notch signaling, loss of notch receptor and increased filopodia, branching formation that results in neovascularization [73].

Delivery of functional miRNAs by means of ECs-derived EVs to recipient ECs was also shown to help the process of *vascular repair and angiogenesis* [74]. In response to hypoxia, the expression of miRNAs, such as miR-210, is upregulated, leading to VEGF-induced chemotaxis to form capillary-like structures in cultured ECs. Upregulation of MiR-210 expression was also found in a surgical murine model of myocardial infarction [75].

## **5. Discussion and conclusions**

By means of their vast secretome, ECs delivery platform sends messages at a distance to circulating blood cells, to other ECs, or to the normal or diseased cells of other organs. ECs complex intercellular communication is possible through the secretory pathways. ECs secretome output may vary, according to the specific vascular bed, whereas ECs phenotype is dictated by their function particularities. The secretome of WPBs is orchestrated by complex, dynamic secretory pathways to meet the versatility of ECs pathophysiology [30]. Novel protein members of the WPBs secretome were

### *Endothelial Secretome DOI: http://dx.doi.org/10.5772/intechopen.106550*

recently identified through a new approach of proximity proteomics, unveiling new facets of WPB exocytosis regulation.

EC-derived EVs are primary effectors in signaling pathways between vascular cells. EVs transfer their cargo from the parent cell to the target cell by: (1) docking to the target cell, and (2) internalization of EVs first, before releasing their content. A pool of internalized EVs by the acceptor (target) cells are sent through an endosomal escape system to unusual delivery destinations [13] and (3) release of EV cargo into the cytosol of the acceptor cell, followed by degradation or return to secretion circuit of the vesicles.

The EVs are secreted by virtually all kinds of eukaryotic cells and in all body tissues and fluids, including blood, saliva, urine, amniotic fluid, cerebrospinal fluid, and breast milk. EVs delivery to the target cells may occur using a cell-specific endocytotic mechanism, dependent on receptor-ligand interactions, via clathrin-dependent endocytosis, via clathrin-independent endocytosis lipid rafts-mediated or caveolaemediated endocytosis, or by common targeting, occurring through pinocytosis, or phagocytosis. It can occur through membrane fusion or via intraluminal vesicles fusion with the endosomal limiting membrane. The sort of the uptake mechanism is given in part by the types of molecular regulators found both on EVs and the targeted plasma membrane of the acceptor cells, because this molecular pair influences the phenotypic traits and behavior of the recipient cells post EV content uptake. Upon shear stress, pH, pressure change, or shock, the ECs release a system of vesicles either into the extracellular space or they reach an additional target cell, which is transformed by this interaction, and that target cell takes on the characteristics of the shredded parent cell.

The ectodomain shedding by proteolytic cleavage of transmembranar protein exterior domain is the posttranslational modification that permits the appearance of new fragments, that function either as receptors or ligands, that control levels of signaling proteins in the recipient cells. This process is not an exemption for transmembranar protein, it rather occurs frequently and is a form of communication between cells. There are still many things unclear about the processes of ectodomain shedding, one question that remains to be elucidated is how the molecular pairing occurs between sheddases and substrates, timing, kinetics, and how sheddases alter the substrate's function and we still must explore their potential as drug targets.

Further, we discussed some aspects related to the posttranscriptional-mediated miRNA regulation of gene expression programs of endothelial cells and their impact on vascular disease. Under disturbed shear flow, miRNAs may be delivered dependent on membrane-bound microparticles [66], or independent of membrane-bound microparticles, with the help of argonaute-2, which protects the miRNAs during delivery to the recipient cells [76].

EVs have beneficial effects, such as anti-inflammatory effects, inhibition of thrombus formation, or vascular repair and angiogenesis [77], but they might have detrimental effects leading to systemic inflammation, atherosclerosis, tilting vascular homeostasis, and thrombotic propensity. Therefore, they could serve as biomarkers of endothelial dysfunction.

EC-derived EVs are frequently found in patients with vascular conditions. EVs found in the plasma of these patients could be used as prognostic factors of vascular disease. Exosomes are still used only in investigational protocols. There are several clinical trials going on trying to prove applications in dermatology (burns) through regeneration and wound healing mediated by exosomes. Some tissular cells can be distinguished from the bloodstream circulating exosomes, but further investigations are needed to delineate the origin of the exosomes in circulation as well as different many facets involved in the creation of the exosomes, in the targeting, transport, and uptake mechanisms (ubiquitin and lipid-mediated) in physiological vs. specific cardiovascular disease condition.

The key advances of endothelial EVs and in particular exosomes for therapeutic purposes are: 1) exosomes can home, 2) can travel systemically without risk of clumping, 3) can travel via local or topical therapy, 4) exosomes cross the "blood– brain barrier," 5) not perceived as foreign, and 6) they deliver miRNA and mRNA and signaling proteins to unite, to mobilize, to integrate, and cytoskeletal proteins to direct the focal adhesion, for matrix-directed acquisition, reduction of proliferation, and matrix production in the target tissue, and cell motion, cell-cycle, anti-apoptotic, and responses to oxidative stress are only a few of the things exosomes can do. 7) No first-pass lung effect, 8) easy to administer, store, and freeze, and 9) the dosage can be controlled.

Further investigations are required to subcategorize the exosomes depending on the cell type or lineage that they are secreted from, and their specific impact on the functions of the vasculature.

A dynamic endothelial cell secretome meets the vasculature bed functional needs through complex secretory pathways EC secretome's constituents could be a readily accessible, rich source of non-toxic markers to monitor and properly assess the risk factors of vascular disease and prognosis. Most importantly, ECs secretome therapeutic potential is emerging for the treatment of various diseases and tissue injuries.

## **Author details**

Luiza Rusu University of Illinois at Chicago, Chicago, Illinois, USA

\*Address all correspondence to<EMAIL_ADDRESS>
© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## **References**

[1] Aird WC. Endothelium as an organ system. Critical Care Medicine. 2004;**32**(Suppl. 5):S271-S279

[2] Dragt BS, van Agtmaal EL, de Laat B, Voorberg J. Effect of laminar shear stress on the distribution of Weibel-Palade bodies in endothelial cells. Thrombosis Research. 2012;**130**(5):741-745

[3] Tunica DG, Yin X, Sidibe A, Stegemann C, Nissum M, Zeng L, et al. Proteomic analysis of the secretome of human umbilical vein endothelial cells using a combination of free-flow electrophoresis and nanoflow LC-MS/ MS. Proteomics. 2009;**9**(21):4991-4996

[4] Charreau B. Secretome and Tunneling nanotubes: A multilevel network for long range intercellular communication between endothelial cells and distant cells. International Journal of Molecular Sciences. 2021;**22**(15):7971-7994

[5] Holthenrich A, Drexler HCA, Chehab T, Naß J, Gerke V. Proximity proteomics of endothelial Weibel-Palade bodies identifies novel regulator of von Willebrand factor secretion. Blood. 2019;**134**(12):979-982

[6] Hayashida K, Bartlett AH, Chen Y, Park PW. Molecular and cellular mechanisms of ectodomain shedding. The Anatomical Record. 2010;**293**(6):925-937

[7] van Breevoort D, van Agtmaal EL, Dragt BS, Gebbinck JK, Dienava-Verdoold I, Kragt A, et al. Proteomic screen identifies IGFBP7 as a novel component of endothelial cell-specific Weibel-Palade bodies. Journal of Proteome Research. 2012;**11**(5):2925-2936

[8] Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. Journal of Thrombosis and Haemostasis. 2003;**1**(7):1335-1342

[9] György B, Módos K, Pállinger E, Pálóczi K, Pásztói M, Misják P, et al. Detection and isolation of cell-derived microparticles are compromised by protein complexes resulting from shared biophysical parameters. Blood. 2011;**117**(4):e39-e48

[10] Tkach M, Théry C. Communication by extracellular vesicles: Where we are and where we need to go. Cell. 2016;**164**(6):1226-1232

[11] Kowal J, Tkach M, Théry C. Biogenesis and secretion of exosomes. Current Opinion in Cell Biology. 2014;**29**:116-125

[12] Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles. 2018;**7**(1):1535750

[13] Mathieu M, Martin-Jaular L, Lavieu G, Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nature Cell Biology. 2019;**21**(1):9-17

[14] Mathieu M, Névo N, Jouve M, Valenzuela JI, Maurin M, Verweij FJ, et al. Specificities of exosome versus small ectosome secretion revealed by live intracellular tracking of CD63 and CD9. Nature Communications. 2021;**12**(1):4389

[15] Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annual Review of Cell and Developmental Biology. 2014;**30**:255-289

[16] Muralidharan-Chari V, Clancy J, Plou C, Romao M, Chavrier P, Raposo G, et al. ARF6-regulated shedding of tumor cell-derived plasma membrane microvesicles. Current Biology. 2009;**19**(22):1875-1885

[17] Weibel ER, Palade GE. New cytoplasmic components in arterial endothelia. The Journal of Cell Biology. 1964;**23**:101-112

[18] Denis C, Methia N, Frenette PS, Rayburn H, Ullman-Cullere M, Hynes RO, et al. A mouse model of severe von Willebrand disease: Defects in hemostasis and thrombosis. Proceedings of the National Academy of Sciences of the United States of America. 1998;**95**(16):9524-9529

[19] Voorberg J, Fontijn R, Calafat J, Janssen H, van Mourik JA, Pannekoek H. Biogenesis of von Willebrand factorcontaining organelles in heterologous transfected CV-1 cells. The EMBO Journal. 1993;**12**(2):749-758

[20] Wagner DD, Saffaripour S, Bonfanti R, Sadler JE, Cramer EM, Chapman B, et al. Induction of specific storage organelles by von Willebrand factor propolypeptide. Cell. 1991;**64**(2):403-413

[21] Valentijn KM, Eikenboom J. Weibel-Palade bodies: A window to von Willebrand disease. Journal of Thrombosis and Haemostasis. 2013;**11**(4):581-592

[22] Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: Processing steps and their intracellular localization. The

Journal of Cell Biology. 1984;**99**(6): 2123-2130

[23] Vischer UM, Wagner DD. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood. 1994;**83**(12):3536-3544

[24] Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell. 1986;**46**(2):185-190

[25] Zenner HL, Collinson LM, Michaux G, Cutler DF. High-pressure freezing provides insights into Weibel-Palade body biogenesis. Journal of Cell Science. 2007;**120**(Pt 12):2117-2125

[26] Lui-Roberts WW, Collinson LM, Hewlett LJ, Michaux G, Cutler DF. An AP-1/clathrin coat plays a novel and essential role in forming the Weibel-Palade bodies of endothelial cells. The Journal of Cell Biology. 2005;**170**(4):627-636

[27] Vischer UM, Wagner DD. CD63 is a component of Weibel-Palade bodies of human endothelial cells. Blood. 1993;**82**(4):1184-1191

[28] Giblin JP, Hewlett LJ, Hannah MJ. Basal secretion of von Willebrand factor from human endothelial cells. Blood. 2008;**112**(4):957-964

[29] Matsushita K, Morrell CN, Cambien B, Yang SX, Yamakuchi M, Bao C, et al. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell. 2003;**115**(2):139-150

[30] Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J. Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;**26**(5):1002-1007

[31] Bonfanti R, Furie BC, Furie B, Wagner DD. PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood. 1989;**73**(5):1109-1112

[32] Padilla A, Moake JL, Bernardo A, Ball C, Wang Y, Arya M, et al. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood. 2004;**103**(6):2150-2156

[33] Denis CV, André P, Saffaripour S, Wagner DD. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice. Proceedings of the National Academy of Sciences of the United States of America. 2001;**98**(7):4072-4077

[34] Pendu R, Terraube V, Christophe OD, Gahmberg CG, de Groot PG, Lenting PJ, et al. P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor. Blood. 2006;**108**(12):3746-3752

[35] Rosenberg JB, Greengard JS, Montgomery RR. Genetic induction of a releasable pool of factor VIII in human endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;**20**(12):2689-2695

[36] Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell. 1997;**89**(2):309-319

[37] Starke RD, Ferraro F, Paschalaki KE, Dryden NH, McKinnon TA, Sutton RE, et al. Endothelial von Willebrand factor regulates angiogenesis. Blood. 2011;**117**(3):1071-1080

[38] Bierings R, Hellen N, Kiskin N, Knipe L, Fonseca AV, Patel B, et al. The interplay between the Rab27A effectors Slp4-a and MyRIP controls hormoneevoked Weibel-Palade body exocytosis. Blood. 2012;**120**(13):2757-2767

[39] Zhou HJ, Qin L, Zhang H, Tang W, Ji W, He Y, et al. Erratum: Endothelial exocytosis of angiopoietin-2 resulting from CCM3 deficiency contributes to cerebral cavernous malformation. Nature Medicine. 2016;**22**(12):1502

[40] Knipe L, Meli A, Hewlett L, Bierings R, Dempster J, Skehel P, et al. A revised model for the secretion of tPA and cytokines from cultured endothelial cells. Blood. 2010;**116**(12):2183-2191

[41] Hol J, Küchler AM, Johansen FE, Dalhus B, Haraldsen G, Oynebråten I. Molecular requirements for sorting of the chemokine interleukin-8/CXCL8 to endothelial Weibel-Palade bodies. The Journal of Biological Chemistry. 2009;**284**(35):23532-23539

[42] Øynebråten I, Bakke O, Brandtzaeg P, Johansen FE, Haraldsen G. Rapid chemokine secretion from endothelial cells originates from 2 distinct compartments. Blood. 2004;**104**(2):314-320

[43] Øynebråten I, Barois N, Hagelsteen K, Johansen FE, Bakke O, Haraldsen G. Characterization of a novel chemokine-containing storage granule in endothelial cells: Evidence for preferential exocytosis mediated by protein kinase a and diacylglycerol. Journal of Immunology. 2005;**175**(8):5358-5369

[44] Chatterjee V, Yang X, Ma Y, Cha B, Meegan JE, Wu M, et al. Endothelial microvesicles carrying Src-rich cargo impair adherens junction integrity and cytoskeleton homeostasis. Cardiovascular Research. 2020;**116**(8):1525-1538

[45] Chironi GN, Boulanger CM, Simon A, Dignat-George F, Freyssinet JM, Tedgui A. Endothelial microparticles in diseases. Cell and Tissue Research. 2009;**335**(1):143-151

[46] Mathiesen A, Hamilton T, Carter N, Brown M, McPheat W, Dobrian A. Endothelial extracellular vesicles: From keepers of health to messengers of disease. International Journal of Molecular Sciences. 2021;**22**(9):4640-4666

[47] Leroyer AS, Ebrahimian TG, Cochain C, Récalde A, Blanc-Brude O, Mees B, et al. Microparticles from ischemic muscle promotes postnatal vasculogenesis. Circulation. 2009;**119**(21):2808-2817

[48] Colombo M, Moita C, van Niel G, Kowal J, Vigneron J, Benaroch P, et al. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. Journal of Cell Science. 2013;**126**(Pt 24):5553-5565

[49] Jaé N, McEwan DG, Manavski Y, Boon RA, Dimmeler S. Rab7a and Rab27b control secretion of endothelial microRNA through extracellular vesicles. FEBS Letters. 2015;**589**(20 Pt B): 3182-3188

[50] Hundhausen C, Schulte A, Schulz B, Andrzejewski MG, Schwarz N, von Hundelshausen P, et al. Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. Journal of Immunology. 2007;**178**(12):8064-8072

[51] Pabois A, Devallière J, Quillard T, Coulon F, Gérard N, Laboisse C, et al. The disintegrin and metalloproteinase ADAM10 mediates a canonical notch-dependent regulation of IL-6 through Dll4 in human endothelial

cells. Biochemical Pharmacology. 2014;**91**(4):510-521

[52] Schulz B, Pruessmeyer J, Maretzky T, Ludwig A, Blobel CP, Saftig P, et al. ADAM10 regulates endothelial permeability and T-cell transmigration by proteolysis of vascular endothelial cadherin. Circulation Research. 2008;**102**(10):1192-1201

[53] Yang J, LeBlanc ME, Cano I, Saez-Torres KL, Saint-Geniez M, Ng YS, et al. ADAM10 and ADAM17 proteases mediate proinflammatory cytokineinduced and constitutive cleavage of endomucin from the endothelial surface. The Journal of Biological Chemistry. 2020;**295**(19):6641-6651

[54] Pabois A, Pagie S, Gérard N, Laboisse C, Pattier S, Hulin P, et al. Notch signaling mediates crosstalk between endothelial cells and macrophages via Dll4 and IL6 in cardiac microvascular inflammation. Biochemical Pharmacology. 2016;**104**:95-107

[55] Oliveira SDS, Chen J, Castellon M, Mao M, Raj JU, Comhair S, et al. Injuryinduced shedding of extracellular vesicles depletes endothelial cells of Cav-1 (Caveolin-1) and enables TGF-β (transforming growth factorβ)-dependent pulmonary arterial hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology. 2019;**39**(6):1191-1202

[56] Hardy MP, Audemard É, Migneault F, Feghaly A, Brochu S, Gendron P, et al. Apoptotic endothelial cells release small extracellular vesicles loaded with immunostimulatory viral-like RNAs. Scientific Reports. 2019;**9**(1):7203

[57] Li Q, Nong A, Huang Z, Xu Y, He K, Jia Y, et al. Exosomes containing miR-122-5p secreted by LPS-induced neutrophils regulate the apoptosis and *Endothelial Secretome DOI: http://dx.doi.org/10.5772/intechopen.106550*

permeability of brain microvascular endothelial cells by targeting OCLN. American Journal of Translational Research. 2021;**13**(5):4167-4181

[58] Jansen F, Yang X, Proebsting S, Hoelscher M, Przybilla D, Baumann K, et al. MicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. Journal of the American Heart Association. 2014;**3**(6):e001249

[59] Jansen F, Yang X, Baumann K, Przybilla D, Schmitz T, Flender A, et al. Endothelial microparticles reduce ICAM-1 expression in a microRNA-222-dependent mechanism. Journal of Cellular and Molecular Medicine. 2015;**19**(9):2202-2214

[60] Jansen F, Zietzer A, Stumpf T, Flender A, Schmitz T, Nickenig G, et al. Endothelial microparticlepromoted inhibition of vascular remodeling is abrogated under hyperglycaemic conditions. Journal of Molecular and Cellular Cardiology. 2017;**112**:91-94

[61] Nong A, Li Q, Huang Z, Xu Y, He K, Jia Y, et al. MicroRNA miR-126 attenuates brain injury in septic rats via NF-κB signaling pathway. Bioengineered. 2021;**12**(1):2639-2648

[62] Njock MS, Cheng HS, Dang LT, Nazari-Jahantigh M, Lau AC, Boudreau E, et al. Endothelial cells suppress monocyte activation through secretion of extracellular vesicles containing antiinflammatory microRNAs. Blood. 2015;**125**(20):3202-3212

[63] Fang Y, Shi C, Manduchi E, Civelek M, Davies PF. MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proceedings of the National Academy of Sciences of the United States of America. 2010;**107**(30):13450-13455

[64] Zhou J, Li YS, Nguyen P, Wang KC, Weiss A, Kuo YC, et al. Regulation of vascular smooth muscle cell turnover by endothelial cell-secreted microRNA-126: Role of shear stress. Circulation Research. 2013;**113**(1):40-51

[65] Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proceedings of the National Academy of Sciences of the United States of America. 2008;**105**(5):1516-1521

[66] Fernández-Hernando C, Suárez Y. MicroRNAs in endothelial cell homeostasis and vascular disease. Current Opinion in Hematology. 2018;**25**(3):227-236

[67] Royo F, Moreno L, Mleczko J, Palomo L, Gonzalez E, Cabrera D, et al. Hepatocyte-secreted extracellular vesicles modify blood metabolome and endothelial function by an arginasedependent mechanism. Scientific Reports. 2017;**7**:42798

[68] Palomo L, Casal E, Royo F, Cabrera D, van-Liempd S, Falcon-Perez JM. Considerations for applying metabolomics to the analysis of extracellular vesicles. Frontiers in Immunology. 2014;**5**:651

[69] Liu Y, Li Q, Hosen MR, Zietzer A, Flender A, Levermann P, et al. Atherosclerotic conditions promote the packaging of functional MicroRNA-92a-3p into endothelial microvesicles. Circulation Research. 2019;**124**(4):575-587

[70] Weilner S, Schraml E, Wieser M, Messner P, Schneider K, Wassermann K, et al. Secreted microvesicular miR-31 inhibits osteogenic differentiation of mesenchymal stem cells. Aging Cell. 2016;**15**(4):744-754

[71] Abid Hussein MN, Böing AN, Sturk A, Hau CM, Nieuwland R. Inhibition of microparticle release triggers endothelial cell apoptosis and detachment. Thrombosis and Haemostasis. 2007;**98**(5):1096-1107

[72] Pérez-Casal M, Downey C, Cutillas-Moreno B, Zuzel M, Fukudome K, Toh CH. Microparticleassociated endothelial protein C receptor and the induction of cytoprotective and anti-inflammatory effects. Haematologica. 2009;**94**(3):387-394

[73] Sheldon H, Heikamp E, Turley H, Dragovic R, Thomas P, Oon CE, et al. New mechanism for notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood. 2010;**116**(13):2385-2394

[74] Jansen F, Stumpf T, Proebsting S, Franklin BS, Wenzel D, Pfeifer P, et al. Intercellular transfer of miR-126-3p by endothelial microparticles reduces vascular smooth muscle cell proliferation and limits neointima formation by inhibiting LRP6. Journal of Molecular and Cellular Cardiology. 2017;**104**: 43-52

[75] Hu S, Huang M, Li Z, Jia F, Ghosh Z, Lijkwan MA, et al. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation. 2010;**122** (11 Suppl):S124-S131

[76] Zhu JJ, Liu YF, Zhang YP, Zhao CR, Yao WJ, Li YS, et al. VAMP3 and SNAP23 mediate the disturbed flow-induced endothelial microRNA secretion and smooth muscle hyperplasia. Proceedings of the National Academy of Sciences

of the United States of America. 2017;**114**(31):8271-8276

[77] Cocozza F, Grisard E, Martin-Jaular L, Mathieu M, Théry C. SnapShot: Extracellular vesicles. Cell. 2020;**182**(1):262.e1

## **Chapter 3**